The role of necroptosis in disease and treatment

Xiaoxiao Liu1,2 | Xin Xie1,2 | Yuanyuan Ren1,2 | Zhiying Shao1,2,3 | Nie Zhang1,2 | Liantao Li1,2 | Xin Ding1,2 | Longzhen Zhang1,2

1 Department of Radiation Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University, Xuzhou, Jiangsu Province, P. R. China
2 Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu Province, P. R. China
3 Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu Province, P. R. China

Abstract

Necroptosis, a distinctive type of programmed cell death different from apoptosis or necrosis, triggered by a series of death receptors such as tumor necrosis factor receptor 1 (TNFR1), TNFR2, and Fas. In case that apoptosis process is blocked, necroptosis pathway is initiated with the activation of three key downstream mediators which are receptor-interacting serine/threonine protein kinase 1 (RIPK1), RIPK3, and mixed lineage kinase domain-like protein (MLKL). The whole process eventually leads to destruction of the cell membrane integrity, swelling of organelles, and severe inflammation. Over the past decade, necroptosis has been found widely involved in life process of human beings and animals. In this review, we attempt to explore the therapeutic prospects of necroptosis regulators by describing its molecular mechanism and the role it played in pathological condition and tissue homeostasis, and to summarize the research and clinical applications of corresponding regulators including small molecule inhibitors, chemicals, Chinese herbal extracts, and biological agents in the treatment of various diseases.

Abbreviations: AD, Alzheimer’s disease; AEC, airway epithelial cell; AKI, acute kidney injury; ALD, alcoholic liver disease; ALI, acute lung injury; ALS, Amyotrophic lateral sclerosis; AMD, Age-related macular degeneration; AP, Acute pancreatitis; ARDS, Acute respiratory distress syndrome; ARHL, Age-related hearing loss; CaMK II, calmodulin-dependent protein kinase II; cIAP1, cellular inhibitor of apoptosis protein 1; CKD, chronic kidney disease; CMV, Murine cytomegalovirus; CNS, central nervous system; COPD, chronic obstructive pulmonary disease; CS, cigarette smoke; DAI, DNA-dependent activator of interferon; FADD, Fas-associated death domain; Fasl, Fas ligand; HSV, herpes simplex virus; IPF, idiopathic pulmonary fibrosis; IRI, Ischemia-reperfusion injury; KPN, Klebsiella pneumonia; MI, Myocardial infarction; MLKL, mixed lineage kinase domain-like protein; mPTP, mitochondrial permeability transition pore; MS, Multiple sclerosis; NEC, necrotizing enterocolitis; Nec-1, Necrostatin-1; OA, Osteoarthritis; PD, Parkinson’s disease; PFT, pore-forming toxin; RA, Rheumatoid arthritis; RGC, retinal ganglion cells; RHIM, RIPK homeotype interaction motif; RIPK1, Receptor-interacting serine/threonine protein kinase 1; RIPK3, receptor-interacting serine/threonine protein kinase 3; RPE, retina pigment epithelial; RSV, Respiratory syncytial virus; S. aureus, Staphylococcus aureus; SIS, Stevens-Johnson syndrome; Spn, Streptococcus pneumonia; TAB 2, TAK1-binding protein 2; TAK1, transforming growth factor-β activated kinase 1; TEN, toxic epidermal necrolysis; TNFR1, TNF receptor; TNF-α, tumor necrosis factor-α; TRADD, TNFR1-associated death domain; TRIF, TIR domain-containing adaptor protein; VILI, ventilator-induced lung injury

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2021 The Authors. MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.

730 | wileyonlinelibrary.com/journal/mco2

MedComm. 2021;2:730–755.
1 | INTRODUCTION

Necroptosis was first recognized in 1988. Laster et al. found that tumor necrosis factor-α (TNF-α) could induce a classical form of apoptosis or a necrotic form of cell death.1 In 1998, Vercammen et al. found two different Fas receptor-related pathways: one leads to apoptosis, the other one directs the cells to necrosis when apoptotic is blocked by caspase inhibitors in this pathway.2 Subsequently, researchers began to be interested in the molecular mechanism of necroptosis. Receptor-interacting serine/threonine protein kinase 1 (RIPK1) is the first core molecule found in this pathway. Degterev et al. named this nonapoptotic death pathway induced by Fas ligand (FasL)/TNFR family as necroptosis.3,4 Then RIPK3 was proved as downstream regulator,5 and the effector mixed lineage kinase domain-like protein (MLKL) of this pathway was found in a short time6 (Figure 1).

As a newly discovered and widely concerned mode of programmed cell death, necroptosis shares the similar morphological characteristics with necrosis such as disintegration of plasma membrane, swelling of organelles, and spillage of cellular contents. Nonetheless, necrosis is a non-regulated programmed death caused by external physical or chemistry stress, such as infection or inflammation at any moment, while necroptosis is a regulated programmed death.7 The key molecules in the necroptosis pathway are RIPK1/3 and MLKL.8 As a supplementary cell death mode for the failure of cell apoptosis, necroptosis is a characteristic cell death mode activated by a unique caspase-independent signaling pathway9,10 and closely related to homeostasis, inflammation, cancer, neurodegeneration, infectious diseases, cardiovascular diseases, a variety of skin diseases, and acute kidney injury (AKI).11–16 In this article, we will discuss the function of necroptosis in homeostasis and diverse diseases, and further reveal the application of necroptosis regulators.

1.1 | The molecular mechanism of necroptosis

Necroptosis occurs when the death receptor tumor necrosis factors (such as TNFR1, TNFR2, and Fas) bind their death receptor ligands (such as TNF-α, FasL) with inhibition or blocking-up in apoptotic pathway. The TNF-α induced necroptosis pathway is generally understood.17 Specifically, TNF-α activates TNFR1 on the cell membrane leading to the structure change of TNFR1. Consequently, TNFR complex is formed by recruiting a series of proteins which includes TNFR1-associated death domain protein (TRADD), RIPK1, TNFR-associated factor 2/5, a cellular inhibitor of apoptosis protein 1 (cIAP1), cIAP2, and ubiquitination complex. TNFR complex I then coordinate numerous downstream signaling pathways through complex patterns, such as ubiquitination and phosphorylation, determining the end of the cell (survival or death). The ubiquitination status of TNFR complex I is important for determining many downstream pathways.18 Polyubiquitinated RIPK1 recruits transforming growth factor-β activated kinase 1 (TAK1), TAK1-binding protein 2 (TAB2), and TAB3 to form a TAK1-TAB2-TAB3 complex which can activate NF-κB signal pathway for cell survival.19 In contrast, the deubiquitination and release of RIPK1 from TNFR complex I promote the formation of TNFR complex II, which can activate downstream cellular apoptosis and necroptosis pathways.20,21 TRADD and Fas-associated death domain (FADD) dissociate from complex I resulting in assembly of complex IIA with pro-caspase-8 and RIPK1. Complex IIA promotes the activation of caspase-8.
and activated caspase-8 causes apoptosis by activating caspase-3. Complex IIb consisting of FADD, RIPK1, and pro-caspase-8 is independent of TRADD and could induce caspase-8-dependent apoptosis. With caspase-8 inhibition, RIPK1 binds RIPK3 via RIPK homeotype interaction motif Rhim (RHIM) containing consensus sequences IQIG (RIPK1) and VQVG (RIPK3) to form complex II c/necrosome, the functional amyloid proteins required for signal transduction and activation of necrosis. Furthermore, it plays a critical role in initiating necroptosis. After the initiation of necroptosis, necrosome promotes the formation of disulfide bond-dependent MLKL polymer by activating the phosphorylation of pseudokinase MLKL on threonine 357/serine 358 (in humans) or serine 345 (in mice), resulting in the assembly of RIPK1-RIPK3-MLKL complex. As a result, MLKL is endowed with the ability to translocate to the plasma membrane to cause cell rupture and the execution of necroptosis. Other death receptors, such as Fas, mainly recruit membrane-associated death complex composed of FADD and caspase-8 after being connecting with its ligand. In the presence of cIAP and the absence of caspase-8, Fas also promote the formation of necrosome by a RIPK3-dependent means. Necroptosis is process to eliminate cells that fails to perform apoptosis. In other words, it can be considered as a supplementary cell death mode of apoptosis.

The regulation of the necroptosis signaling pathway mainly targets at three key molecules, RIPK1, RIPK3, and MLKL. The unique protein-protein interaction domain on the C-terminus of RIPK1 and RIPK3 is known as RHIM, mediating the interaction between RIPK1 and RIPK3. Although RIPK1 is a signal molecule necessary to activate RIPK3 in the TNF-induced necroptosis pathway, it is not a prerequisite for other necroptosis pathways. RIPK3 can open the mitochondrial permeability transition pore (mPTP) by activating Ca$^{2+}$/calmodulin-dependent protein kinase II (CaMK II). The mPTP opener eventually leads to necroptosis of cardiomyocytes. In addition to being activated by RIPK1, RIPK3 can also be activated by other proteins containing RHIM domain including TIR domain-containing adaptor protein (TRIF) and DNA-dependent activator of interferon regulatory factors (DAI). For instance, toll-like receptor 3 (TLR3) or TLR4 directly activates TRIF-RIPK3-MLKL pathway of necroptosis through the synergistic action between TRIF containing RHIM and RIPK3. RIPK3 is a signal integration molecule that can be used for necroptosis demand. It can interact with other RHIM-containing signal molecules through RHIM, leading to different necroptosis pathways.

MLKL is considered to be a pseudokinase based on the lack of two of the three conserved catalytic residues on its kinase-like domain. MLKL activation is a continuous process starting with kinase-like domain dimerization followed by the internal coiled-coil region self-assembly and final formation of appropriate MLKL oligomer. The direct outcome of RIPK3-induced MLKL phosphorylation is the dimerization of the kinase-like domain of MLKL. The necessary condition for MLKL oligomerization and function guarantee is that MLKL self-assembles through the internal coiled-coil region. Besides human MLKL, functional and structural analysis showed that kinase-like domain dimerization is conserved in mammalian species, indicating a common step in the process of RIPK3-induced MLKL activation. With the ability to directly bind to lipids, polymerized MLKL compromise the integrity of cell membrane by forming membrane permeability pores, which results in necroptosis. Besides necroptosis, recent researches show that MLKL also cross-talks with other regulatory cell death pathways, translocates to the nucleus to regulate gene expression, binds lipids to destroy bacteria, and inhibits specific metabolic processes and tissue regeneration.

1.2 The characteristic difference between necroptosis and apoptosis

Both necroptosis and apoptosis are regulated by the machinery at molecular level. Apoptosis is a normal biological phenomenon that most cells in the body can keep a certain developmental procedure to maintain a stable internal environment. While apoptosis is a highly regulatory process of insoluble cell death induced by caspase family, necroptosis is activated by a unique caspase-independent signaling pathway mainly depending on RIPK1/RIPK3/MLKL complex. The morphological features of apoptosis include cell shrinkage, cell membrane blebbing, chromatin condensation, apoptotic body formation, and rapid engulfment by surrounding phagocytes. No overflow of contents occurs during apoptosis, hence, no inflammatory immune response. In contrast, necroptosis is a kind of cytolytic death. Due to the rapid loss of the plasma membrane integrity, proinflammatory content leak out of the cells causing a wide range of inflammatory reactions.

1.3 Necroptosis in homeostasis and diseases

Necroptosis regulation is crucial for maintaining tissue homeostasis and preventing inflammation. The loss of key proteins in the apoptosis pathway, such as caspase-3, apaf-1, caspase-7, and Bax/Bak, has minimal effect on embryonic development. The deficiency of caspase-8 and FADD, however, is fatal to embryonic cells at around E10.5
embryonic day. The explanation of this phenomenon has remained controversial until researchers discovered that caspase-8 and FADD are needed to suppress RIPK1 and RIPK3 expression during early embryonic development. Ablation of RIPK3 completely rescued the fateful death of caspase-8-deficient mice. In line with this, the loss of RIPK1 allowed normal embryogenesis in FADD-deficient mice. In immune system, necroptosis inhibition by the caspase-8 and FADD supports the survival of T cells during clonal expansion. Signaling pathways that control the immune response, cell death, and cell survival may have a crucial role in regulating tissue homeostasis and inflammation. FADD and caspase-8 prevent intestinal inflammation by inhibiting necroptosis. FADD deficiency leads to TNFR1-mediated RIPK3-dependent necroptosis contributing to the intestinal barrier destruction and bacterial-driven inflammation. Necroptosis of epithelial cells may also cause colitis. Inhibition of RIPK3-MLKL-dependent necroptosis and FADD-caspase-8-dependent cell apoptosis totally prevents the development of animal skin lesions. Inhibition of the key molecules in necroptosis pathway helps to prevent periodontal disease. All of the previous researches have shown that inhibiting necroptosis is of importance to tissue homeostasis maintenance and inflammation prevention.

Necroptosis has two sides in cancer and its development. On the one hand, the downregulation of RIPK3 or MLKL is related to poor prognosis of various types of cancer, such as breast cancer, colorectal cancer, acute myeloid leukemia, head and neck squamous cell carcinoma, melanoma, cervical squamous cell carcinoma, gastric cancer, and ovarian cancer. SN38 (topoisomerase inhibitor) is proved to inhibit cell proliferation in colon cancer by inducing DNA damages and promoting necroptosis. On the other hand, the upregulation of RIPK3 or RIPK1 is related to the development of glioma, lung cancer, and pancreatic cancer. Necroptosis can also promote metastasis by promoting inflammation or tumor cells-induced necroptosis in endothelial cells. Necrostatin-1 (Nec-1), a specific inhibitor of necroptosis, can reduce inflammation and colitis-related tumor formation (Tables 1, 2).
| Organ/System       | Diseases       | Observations                                                                 | References |
|-------------------|----------------|------------------------------------------------------------------------------|------------|
| Nerve system      | PD             | RIPK1, RIPK3, and MLKL were upregulated in the substantia nigra of PD-derived postmortem tissue | 56         |
|                   | AD             | RIPK1, MLKL, and pMLKL were increased in human AD brains                      | 180        |
|                   | MS             | RIPK1, RIPK3, and MLKL were increased in cortical lesions in human MS brain samples | 60         |
| Cardiovascular    | Aortic aneurysms| RIPK1 and RIPK3 were increased in human abdominal aortic aneurysm             | 74         |
|                   | Atherosclerosis| The expressions of RIPK3 and MLKL were elevated in humans with unstable carotid atherosclerosis | 77         |
| Pulmonary         | COPD           | The pRIPK3, MLKL, and pMLKL were increased in lung of patients with COPD       | 51         |
|                   | IPF            | RIPK3 and p-MLKL were increased in the lungs of IPF patients                  | 91         |
| Liver             | Alcoholic hepatitis | RIPK3 was increased in liver tissues of human with alcoholic liver disease |
|                   | NEC            | RIPK1, RIPK3, and MLKL were significantly upregulated in NEC patients tissue  | 54         |
| Joint             | Osteoarthritis | RIPK1 and RIPK3 were significantly upregulated in cartilage from OA patients | 121, 122   |
| Cancers           | Glioblastoma   | The worse prognosis of glioblastoma was associated with upregulated RIPK1    | 127        |
|                   | Lung cancer    | The worse prognosis of lung cancer was associated with upregulated RIPK1     | 129        |
|                   | MDS            | The worse prognosis of MDS was associated with upregulated RIPK1             | 128        |
|                   | Breast cancer   | The better prognosis of breast cancer was associated with increased RIPK1    | 131        |
|                   | Colorectal cancer | The better prognosis of colorectal cancer was associated with increased RIPK3 and MLKL | 132–134    |
|                   | Melanoma       | The better prognosis of melanoma was associated with increased RIPK3         | 135        |
|                   | Gastric cancer | The better prognosis of gastric cancer was associated with increased MLKL   | 136        |
|                   | Ovarian cancer | The better prognosis of ovarian cancer was associated with increased MLKL   | 137        |
|                   | HNSCC          | The worse prognosis was associated with decreased RIPK1                      | 138        |
|                   | CSCC           | The worse prognosis was associated with decreased MLKL                       | 139        |
| Infections        | S. Pneumonia infections | RIPK3-initiated necroptosis was essential for host defense against S. pneumonia | 169        |
| Skin diseases     | SJS/TEN        | RIPK3 functioned as a diagnostic and severity marker for SJS/TEN             | 179        |
|                   | Psoriasis      | RIPK1 and MLKL were increased in human psoriasis                             | 178        |

AD, Alzheimer’s disease; COPD, chronic obstructive pulmonary disease; CSCC, cervical squamous cell carcinoma; HNSCC, Head and neck squamous cell carcinoma; IPF, Idiopathic pulmonary fibrosis; MDS, Myelodysplastic syndromes; MS, Multiple sclerosis; NEC, necrotizing enterocolitis; PD, Parkinson’s disease; SIS, Stevens–Johnson syndrome; TEN, toxic epidermal necrolysis.

Necroptosis is also involved in ischemia-reperfusion injury (IRI)-induced AKI has necroptosis. Compared with wild-type mice, the level of RIPK1/3 in the heart of ischemic mice is significantly higher. In the acute IRI mouse model, RIPK3 deletion protects the heart from necroptosis induced by IRI and reduces the area of myocardial infarction (MI). Nec-1 could protect heart from both the short- and long-term effects of myocardial ischemia by reducing cell necroptosis and the area of MI and maintaining long-term heart function. Meanwhile, inhibition of RIPK1 expression can block ischemia-induced astrocyte necrosis. In liver, lung, kidney, and intestinal diseases, blocking necroptosis can reduce inflammation and contribute to reducing damage and protecting organs. In alcoholic hepatitis, RIPK3 increases after drinking, whereas RIPK3 deficiency can protect the liver from alcohol-mediated damage by reducing the steatosis and inflammatory effects of ethanol on liver cells. In chronic obstructive pulmonary disease (COPD), Nec-1 can reduce inflammation. In airway epithelial cells (AECs), endoplasmic reticulum chaperone protein GRP78 promotes smoking-induced inflammation, which may be related to the upregulation of necroptosis and the NF-κB pathway. Necroptosis mediates inflammatory response of macrophages induced by cigarette smoke (CS). In acute lung injury (ALI), necroptosis in hypoxia-induced neonatal lung injury mice can be weakened by the deletion of the RIPK3 gene. RIPK3 deficiency mice sur-
### TABLE 2  The role of necroptosis in animal models of diseases

| Organ/System       | Diseases            | Modeling method            | Gene knockout /Inhibitor                                                                 | Observations                                                                                                                                                                                                                      | References |
|--------------------|---------------------|---------------------------|----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Nerve system diseases | Ischemic stroke      | Middle cerebral artery occlusion | RIPK1Δ/Δ, RIPK1K45A/K45A, RIPK3−/−, MLKL−/−, Nec-1 | RIPK1 kinase-dead mutants (Nec-1 inhibitor), RIPK3 deficiency, and MLKL deficiency could protect mice from acute ischemic stroke by blocking necroptosis.                                                                                   | 36, 180    |
| PD                 | 6-OHDA injected in the right striatum | RIPK3−/−, MLKL−/−, Nec-1 | Inhibition of RIPK1 and genetic ablation of MLKL and RIPK3 could decrease dopaminergic neuron degeneration in preclinical models of PD.                                                                                                      | 60         |
| AD                 | AlCl3-induced       | Nec-1, NSA                | Nec-1 and NSA could suppress necroptosis in AD brain.                                                                                                  | 62, 63     |
| ALS                | Optn−/− mice model  | RIPK1Δ/Δ, RIPK3−/−, Nec-1 | RIPK1 kinase-dead mutants (Nec-1 inhibitor), RIPK3 deficiency improved motor performance.                                                             | 65         |
| MS                 | Cuprizone           | Nec-1                     | The demyelination and disease development were inhibited by Nec-1 in multiple sclerosis.                                                            | 68         |
| ARHL               | Aged mice           | None                      | The protein expressions of RIPK1, RIPK3, and MLKL were increased in aged mice.                                                                    | 69         |
| Cardiovascular diseases | Myocardial infarction | LADCA ligation            | RIPK1−/−, Nec-1 | RIPK1 inhibitor and RIPK3 deficiency could reduce the infarct size.                                                                                                                      | 49         |
| Aortic aneurysms    | Elastase            | RIPK3−/−, Nec-1, GSK074 | Nec-1 and GSK074, the necroptosis inhibitors, could attenuate the aortic expansion in mouse model.                                                | 74–76      |
| Atherosclerosis     | Apoe (-/-) mice model | Nec-1                     | Nec-1 could reduce the degree of in atherosclerosis mice model.                                                                                       | 77         |
| Diabetic Cardiomyopathy | Streptozotocin     | RIPK3−/− | The deficiency of RIPK3 could relieve myocardial injury and improve cardiac function.                                                               | 78         |
| Pulmonary diseases  | COPD                | Cigarette Smoke           | RIPK3−/−, MLKL−/−, Nec-1 | RIPK1 inhibitor, RIPK3−/− or MLKL−/− mice could attenuate C5-induced airway inflammation.                                                                                | 51, 81     |
| ARDS               | Oleic acid          | RIPK3−/−, Nec-1            | RIPK1, RIPK3, and MLKL were remarkably upregulated in lung tissue of ARDS rat model. Noc-1 or Knocking out RIPK3 ameliorated the lung tissue injury.                               | 82–84      |
| Asthma             | Inoculated with RSV | RIPK1−/− | Inhibition of the RIPK1 and MLKL could protect the mice from asthma.                                                                                           | 90         |
| IPF                | Bleomycin           | RIPK3−/−, Nec-1            | Nec-1 and RIPK3 deficiency could protect the AECs from Bleomycin by decreasing p-MLKL expression.                                                   | 91         |
| Acute lung injury  | Ventilator          | RIPK3−/−                   | Ventilator or hyperoxia-induced lung injury could alleviate in RIPK3-deficient model.                                                                   | 92, 93     |
| Liver diseases     | Alcoholic hepatitis | Ethanol                   | RIPK3 deficiency had a protective effect on ethanol liver injury.                                                                                  | 90         |

(Continues)
| Organ/System | Diseases | Modeling method | Gene knockout /Inhibitor | Observations | References |
|-------------|----------|----------------|--------------------------|--------------|------------|
| Acute liver injury | Acetaminophen | RIPK3<sup>-/-</sup>, Nec-1 | Using Nec-1 or RIPK3 deficient mice could protect the liver. | 102, 103 |
| Listeria monocytogenes | RIPK1<sup>-/-</sup> | RIPK1 deletion could protect the liver. | 104 |
| Concavavulin A | MLKL<sup>-/-</sup>, Nec-1 | Treating with Nec-1 or MLKL deficient mice could protect the liver. | 105 |
| Pancreatic Diseases | Acute pancreatitis | Caerulein | The inhibition of necroptosis mediated by RIPK3 and MLKL had a protective effect in AP. | 106 |
| Enteric diseases | Intestinal injury | Mimic heat stroke | Nec-1 or GSK872 could significantly reversed intestinal injury. | 107 |
| Renal diseases | Acute kidney injury | Renal pedicles were clamped for 30 min | RIPK1<sup>KD/KD</sup>, RIPK3<sup>-/-</sup>, MLKL<sup>-/-</sup> | RIPK1 KD mutants, RIPK3, and MLKL deficiency could alleviate acute kidney injury by decreasing necroptosis. | 111, 113, 114 |
| | Kidney allograft rejection | RIPK3<sup>-/-</sup> | RIPK3 deficiency could preserve the function of kidney allografts. | 115 |
| Chronic kidney disease | Subtotal nephrectomy surgery | RIPK3<sup>-/-</sup>, MLKL<sup>-/-</sup>, Nec-1 | Renal function and renal pathologic changes were significantly improved after RIPK3 or MLKL deficiency or administration of Nec-1. | 116 |
| Diabetic nephropathy | None | Cassia auriculata ethanol leaf extract could improve the renal dysfunction and pathophysiology by inhibiting RIPK1/RIPK3. | 91 |
| Joint diseases | Rheumatoid arthritis | Collagen | RIPK1, RIPK3, and pMLKL were significantly upregulated in vivo and vitro. Nec-1 could protect articular cartilage injury. | 118 |
| Osteoarthritis | ACLT | Nec-1 | The rats were protected from trauma-induced cartilage degradation and limb pain by Nec-1. | 121 |
| Cancers | AML | Tumor-bearing mice | RIPK3-KD | The worse prognosis was associated with downregulated of RIPK3. | 141 |

(Continues)
| Organ/System | Diseases | Modeling method | Gene knockout /Inhibitor | Observations | References |
|-------------|----------|-----------------|---------------------------|--------------|------------|
| Ocular diseases | Glaucoma (Retinal I/R injury) | Infusion into the anterior chamber | Nec-1 | RIPK3 expression was rapidly increased in the mice retinas I/R. Nec-1 could protect the histoarchitecture and thickness of the inner retina. | 149, 147 |
| | | | | | |
| | AMD | NaIO3, sodium iodate, idoacetic acid | Nec-1 | RIPK1 inhibitor could prevent RPE cells from necroptosis in retinal degeneration. | 150, 151 |
| | Retinitis pigmentosa | Rdi0 mouse model | RIPK3−/− | RIPK1 and RIPK3 were increased in the degenerative retina. RIPK3 deficiency reduced cone cell death. | 152 |
| Infections | Viral infections | Vaccinia virus, Influenza A virus, West-Nile virus, HSV-1 | RIPK3−/− | RIPK3−/− mice were much more susceptible to viral infection. Necroptosis could result in the loss of CD4+ T cells. | 154, 157, 158 |
| | | | | | |
| | HIV | | Nec-1 | Nec-1 could protect CD4+ T from the damage of HIV in cell lines. RIPK3 silencing could restore the proliferation potential of CD8+ T cells from HIV-infected patients. The necroptosis of CD4+ T cells was induced by Pmkl | 159–164 |
| | COVID-19 | None | | Inhibiting necroptosis protected mice from pathology and death induced by TNF-α and IFN-γ in COVID-19 infected. | 162 |
| | CMV, HSV | None | | CMV and HSV encoded caspase-8 inhibitors to promote necroptosis. | 163 |
| Bacterial infections | Salmonella | | None | The suppression of necroptosis mediated by caspase-8 reduced inflammatory damage in intestinal Salmonella infection. | 172 |
| | EPEC | None | | EspL decreases the expressions of RIPK1, RIPK3, and TRIF leading to restricting necroptosis during infection | 173 |
| | Francisella | None | | Francisella was proved to induce necroptosis | 174 |
| | OralT. gondii | None | | Deletion of RIPK3 could significantly improve survival after infection | 175 |
| | Angiostrongylus cantonensis | None | | RIPK3, pRIPK3, pMLKL, and TNF-α were increased by activated microglia caused the necroptosis of neurons. | 49 |
| Parasite infections | Vitiligo | None | | Oxidative stress induced melanocyte death through the RIPK1 signaling pathway. | 177 |
| | Psoriasis | None | | Inhibition of RIPK1 or MLKL could reduce inflammation of psoriasisform dermatitis in mice. | 178 |

ACL, anterior cruciate ligament transection; AD, Alzheimer’s disease; AMD, age-related macular degeneration; AML, acute myeloid leukemia; ARDS, Acute respiratory distress syndrome; ARHL, Age-related hearing loss; ALS, Amyotrophic lateral sclerosis; CMV, Murine cytomegalovirus; COPD, Chronic obstructive pulmonary disease; DMM, destabilisation of the medial meniscus; EPEC, enteropathogenic Escherichia coli; HIV, Human immunodeficiency virus; HSV, herpes simplex virus; IOP, intraocular pressure; IPP, Idiopathic pulmonary fibrosis; I/R, ischemia-reperfusion; LADCA, left anterior descending coronary artery; MS, multiple sclerosis; PD, Parkinson’s disease; RSV, respiratory syncytial virus.
vive form ventilator-induced lung injury by significantly reducing systemic and pulmonary inflammation. From AKI to chronic kidney disease (CKD), under the regulation of IRI, the expression and interaction of RIPK3 and MLKL can induce necrosis of proximal renal tubular cells and promote the activity of inflammasome. Knocking out RIPK3 or MLKL protects renal tubular cells from necroptosis and inflammatory activation and prevents renal interstitial fibrosis after IRI. Necroptosis is activated in a TLR4-dependent manner in the intestine of mice with necrotizing enterocolitis (NEC) and specifically upregulated in differentiated epithelial cells of immature ileal. Genes and drugs inhibiting necroptosis reduce mucosal inflammation and intestinal epithelial cell death in experimental NEC (Tables 1, 2).

The above is a brief description of necroptosis’ role in tissue homeostasis, cancer, IRI, and inflammation. Necroptosis is involved much more than these including infections, neurodegenerative diseases, cardiovascular diseases, digestive system disease, pulmonary diseases, renal diseases, joint diseases, ocular diseases, skin diseases, and cancers (Figure 3). Details will be discussed as below.

### 2 NECROPTOSIS IN HUMAN DISEASES AND ANIMAL MODELS

#### 2.1 Nerve system diseases

**2.1.1 Necroptosis in IRI**

Ischemic stroke is a devastating brain injury usually resulting from thrombus/emboli within the cerebrovascular system. Degterev et al. provided the first example of active necrotic cell death in vivo and demonstrated that necroptosis plays a key role in the delayed ischemic brain injury following middle cerebral artery occlusion. Furthermore, the infarct volume was significantly reduced after the administration of Nec-1. Interestingly, Newton and his colleagues confirmed that loss of RIPK3 had no effect on hypoxia-induced cerebral edema or infarct volume in the major cerebral artery occlusion stroke model. But, Zhang et al. indicated that necroptosis played a crucial role in acute ischemic stroke. RIPK1 kinase-dead mutants, deficiency of RIPK3 or MLKL could prevent acute ischemic stroke through blocking necroptosis. Together these data emphasize that RIPK1 inactivation (Nec-1 inhibitor), RIPK3 deficiency, or MLKL deficiency should be examined to support the role of necroptosis in disease. Furthermore, inflammation is also a pathologic change that occurs after a stroke, the activity of RIPK1 and RIPK3 is associated with the activation of inflammatory-related signal pathways in acute ischemic stroke. Inhibition of necroptosis could reduce cell death, meanwhile making the inflammatory response to be a protective reaction. Yang et al. showed that ischemia induced a neuron-dominated necroptosis through the RIPK3/MLKL pathway. Ablating RIPK3 or MLKL could activate the microglia/macrophages from M1 type, which expresses inflammatory factors and helps to remove dead cells and clear tissue debris, to the M2 type, which expresses anti-inflammatory and growth factors to repair the damage of brain tissue in the ischemic cortex.

**2.1.2 Parkinson’s disease**

Parkinson’s disease (PD) is one of the most important neurodegenerative disorders associated with the progressive degeneration of dopaminergic neurons in the substantia nigra and depletion of dopamine release in the striatum. Previous studies indicated that necroptosis was activated in postmortem brain tissue of PD patients and a toxin-based mouse model of PD. Expressions of RIPK1, RIPK3, and MLKL were elevated in the substantia nigra of PD-derived postmortem tissue. Wu et al. found that Nec-1 could provide protection and increase PC12 cell viability in PD models. Inhibition of RIPK1 and genetic ablation of MLKL and RIPK3 could decrease dopaminergic neuron degeneration in preclinical models of PD. Altogether, these studies support the idea that necroptosis may be a new target to prevent axonal degeneration in PD.

**2.1.3 Alzheimer’s disease**

Alzheimer’s disease (AD) is a devastating neurodegenerative disease with no effective therapies so far. A previous study has found that the expressions of RIPK1, MLKL, and pMLKL were significantly increased in human AD brains compared to their age-matched control counterparts. Accordingly, the levels of phosphorylated RIPK1, RIPK3, and MLKL were markedly higher in the AD rats compared to the control littermates. Treatment with RIPK1 inhibitor (Nec-1) and MLKL inhibitor (NSA) could suppress necroptosis in AD brain. It further confirmed that necroptosis drives neuron death in AD.

**2.1.4 Amyotrophic lateral sclerosis**

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease of the motor system characterized by the progressive loss of motor neurons in the brain and spinal cord, which leads to muscle weakness and eventual paralysis. Researchers have confirmed that the mechanism of neurodegeneration involves necroptosis in
FIGURE 3  Necroptosis is involved in a variety of diseases, including infections, neurodegenerative diseases, cardiovascular diseases, cancers, pulmonary diseases, digestive system disease, renal diseases, joint diseases, ocular diseases, and skin diseases.

both mouse mutant SOD1 and the human ALS in vitro disease models. By pharmacological and genetic interventions targeting RIPK1, it confirmed that manipulating the necroptosis pathway could prevent motor neurons demise. Moreover, Ito et al. showed that the expressions of RIPK1, RIPK3, and pMLKL were elevated in the optineurin (a gene implicated in both familial and sporadic ALS) deficient mice. Therefore, treatment targeting these proteins normalized motor functions and improved axonal degeneration.

2.1.5  Multiple sclerosis

Multiple sclerosis (MS), is an autoimmune demyelinating and neurodegenerative disorder of the central nervous system (CNS). It is the leading cause of neurologic disability in young adults with no known cure. Ofengeim et al. found that the necroptosis markers, RIPK1, RIPK3, and MLKL, were activated in the cortical lesions of human MS pathological samples. Activation of necroptotic signaling often occurred in macroneurons in cortical layers II–III, but little expression in other cell types. All these findings show that necroptosis represents a new therapeutic target in MS treatment. Inhibition of RIPK1 could protect against oligodendrocyte cell death and attenuate demyelination in the animal models of MS.

2.1.6  Age-related hearing loss

Age-related hearing loss (ARHL) is the most prevalent progressive neurodegenerative disorder in the elderly and is presently untreatable. Previous studies have shown that the levels of necroptosis markers, including RIPK1, RIPK3, and MLKL, were significantly elevated in aged mice.
compared to young mice. Considering all of this evidence, it seems that necroptosis plays a crucial role in cochlear aging in vivo.69

2.2 | Cardiovascular diseases

2.2.1 | Myocardial infarction

MI is a life-threatening emergency, caused by the blockage of coronary artery. Luedde et al. first proved that the RIPK3 expression was elevated in ischemic portions of mouse hearts undergoing left anterior descending coronary artery ligation.70 Deficiency of RIPK3 could diminish inflammatory response and reduce the infarct size in an acute I/R model, even have a long-term cardioprotective effect.33,70 Along a similar line, administration of Nec-1 also has a cardioprotective by lessening the death of myocardial cell and infarct size in I/R injury.71–73 Therefore, inhibition of necroptosis may be amenable as a potential MI therapeutic modality.

2.2.2 | Aortic aneurysms

Aortic aneurysms are a common vascular disease in Western populations virtually involving any portion of the aorta. The most common locations are the infrarenal abdominal and ascending aortic regions in human. Aortic aneurysms are manifested as the progressive dilation with a high risk for death due to rupture. Wang and his colleagues observed that the expressions of RIPK1 and RIPK3 were elevated in human abdominal aortic aneurysm, especially medial smooth muscle cells, and the level of RIPK3 was also elevated in the mouse model of abdominal aortic aneurysm. Overexpression of RIPK3 could trigger SMC necroptosis while deletion of RIPK3 could impair inflammatory gene expression in aortic SMCs.74 Several studies have found that both Nec-1 and GSK074, the necroptosis inhibitors, attenuate the aortic expansion in mouse models of abdominal aortic aneurysm.75,76 Therefore, these results indicate that inhibiting necroptosis pathway represents a potential strategy for treating aortic aneurysms.

2.2.3 | Atherosclerosis

Atherosclerosis is a chronic inflammatory disease of the arterial wall, leading to acute thrombus and subsequent MI or stroke, and is a leading cause of cardiovascular mortality. Karunakaran et al. confirmed that the levels of RIPK3 and MLKL were higher in patients with unstable carotid atherosclerosis. Low-density lipoprotein promotes RIPK3 and MLKL transcription and phosphorylation. Nec-1 could reduce the lesion size and markers of plaque instability in mice model. Collectively, these findings suggest that necroptosis can be targeted as a therapeutic tool for treating unstable atherosclerosis.77

2.2.4 | Diabetic cardiomyopathy

Chen et al. demonstrated that necroptosis was involved in diabetic cardiomyopathy. Deficiency of RIPK3 mitigated myocardial injury, improved cardiac function, suppressed CaMK II activation, and reduced necroptosis in mice with diabetic cardiomyopathy mice. Moreover, CaMK II activation and necroptosis augment in diabetic cardiomyopathy were achieved via a RIPK3-dependent manner. These findings may open novel avenues for therapeutic strategies against diabetic cardiomyopathy.78

2.3 | Pulmonary diseases

2.3.1 | Chronic obstructive pulmonary disease

COPD is a chronic smoking-related lung disease, characterized by persistent respiratory symptoms and progressive airflow obstruction, associated with significant morbidity and mortality, killing more than 3 million people worldwide every year.79 In recent years, there has been an increasing amount of literature that has shown that necroptosis plays a vital role in this fatal disease. Mizumura et al. demonstrated that necroptosis could potentially contribute to COPD pathogenesis through activation of RIPK3 and mitophagy induced by CS exposure. Furthermore, they also discovered the elevated expression of RIPK3 was in human COPD lung.80 Similarly, Lu et al. found that the total MLKL protein in the epithelium and macrophages along with the pRIPK3 and pMLKL in lung tissue were elevated in patients with severe COPD. Deficiency of RIPK3 or MLKL could attenuate CS-induced airway inflammation, airway remodeling, and emphysema.82 In mice model, CS-induced necroptosis and DAMP release could initiate neutrophilic airway inflammation in mice. Treatment with the necroptosis inhibitor Nec-1 could attenuate neutrophilic inflammation induced by CS accordingly.81 In general, these findings indicate that necroptosis plays a pathogenic role in COPD and indicate that it could be a potential therapeutic target in COPD treatment.

2.3.2 | Acute respiratory distress syndrome

Acute respiratory distress syndrome (ARDS) is a syndrome of acute respiratory failure caused by noncardiogenic
pulmonary edema, characterized by rapidly progressive dyspnea, tachypnea, and hypoxemia. ARDS is thought to occur when a pulmonary or extrapulmonary insult causes the release of inflammatory mediators, promoting inflammatory cell accumulation in the alveoli, and microcirculation of the lung. Previous studies have shown that the expressions of RIPK1, RIPK3, and MLKL were remarkably elevated in lung tissue from the rat model of ARDS. Treatment with Nec-1 could ameliorate pulmonary function dramatically in osteoarthritis (OA)-induced ARDS rats. Furthermore, Nec-1 could downregulate RIPK1-RIPK3-MLKL signal pathway and inhibit inflammatory response by reducing neutrophil infiltration and protein leakage in a rat model of ARDS. Interestingly, Wang et al. had shown that RIPK3 was significantly increased in the severe ARDS model, while accompanied pRIPK3 and MLKL were increased in the mild ARDS group. Knocking out RIPK3 attenuated the hypothermia symptom, ameliorated the lung tissue injury, and increased the survival rate.

2.3.3 Asthma

Asthma is a chronic heterogeneous disease of the lower airways characterized by chronic inflammation, airway remodeling, and airway hyper-reactivity leading to cough, wheeze, breathing difficulties, and chest tightness. Previous studies have shown that eosinophil cytolysis takes place through RIPK3-MLKL-dependent necroptosis, which can be negatively regulated by autophagy. Treatment with GW806742X, a human and murine necroptosis inhibitor, blocked necroptosis and IL-33 release in vitro and reduced eosinophilia in Aspergillus fumigatus extract-induced asthma in vivo. In a mouse model of asthma exacerbations induced by in house dust mite for inflammation and double-stranded RNA for exacerbation, RIPK3 and phosphorylation of MLKL were increased in IFN-β–/– mice, so the absence of IFN-β may augment markers of necrotic cell death at exacerbation. Particulate matter 2.5 μm is a well-recognized risk factor for asthma. Zhao et al. have shown that PM2.5 could enhance airway hyperresponsiveness, which was induced by necroptosis-related inflammation. Respiratory syncytial virus (RSV)-associated bronchiolitis is the major cause of morbidity and mortality in infancy worldwide. And severe RSV-bronchiolitis during infancy is associated with increased asthma risk in childhood. RSV infection induces the necroptosis of AEC. Inhibition of the RIPK1 and MLKL can ameliorate the severity of viral bronchiolitis in mice and prevent the later progression to asthma. The above-mentioned results suggested that inhibition of necroptosis may be a new approach to limit the severity of bronchiolitis and break its nexus with asthma.

2.3.4 Idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive idiopathic interstitial pneumonia, characterized by an abnormal fibrotic response involving vast areas of the lungs and ultimately respiratory failure and death. Lee et al. showed that the levels of RIPK3 and pMLKL were markedly raised in human IPF lungs, which indicated necroptosis might contribute to IPF development. RIPK3, HMGB1, and IL-1β were also increased in the lung fibrosis models induced by bleomycin (BLM). Decreased BLM-induced DAMPs secretion and attenuated lung inflammation and fibrosis were observed in RIPK3-deficient mice model. In general, blockage of necroptosis may be a promising therapeutic approach for IPF.

2.3.5 Acute lung injury

RIPK3-mediated necroptosis was detected in the hypoxia-induced lung injury of neonatal mice, which was attenuated by the deletion of RIPK3. Similarly, RIPK3-mediated necroptosis also involved in the development of an LPS-induced ALI mouse model. Inhibition of RIPK3 could significantly reduce LPS-induced necroptosis and NLRP inflammasome activation accompanied by reduced production of IL-1β and IL-18 production and inflammatory cell infiltration. RIPK3-deficient mice, but not MLKL deficiency, could protect the mice against ventilator-induced lung injury in a fatty acid β-oxidation-dependent manner. Treatment with Nec-1 could attenuate lung injury, systemic and lung inflammation, and improve survival rate in neonatal mice with sepsis.

2.4 Liver disease

Liver diseases are the major causes of illness and death worldwide ranging from hepatitis B, hepatitis C, alcoholic liver disease (ALD), nonalcoholic fatty liver disease, hepatic fibrosis, cirrhosis, liver failure, and HCC. Liver injury is generally classified into two clinical subtypes by duration: acute and chronic. Acute liver failure, the most extreme form of acute liver injury, is a clinical syndrome occurred in patients without pre-existing liver disease and characterized by coagulopathy and encephalopathy. Chronic liver injury is characterized by the presence of persistent liver damage and hepatitis from inflammation or intracellular stress responses.

Previous research has shown that phosphorylated MLKL translocated to the plasma membrane and then executed cell death. This process is driven by RIPK3-dependent phosphorylation and is the necessary step of
necroptosis. Hence, RIPK3 and MLKL are considered to be the important components of activated necroptosis. It is worth noting that the expression of RIPK3 is absent under basal conditions, which is contrary to MLKL. Based on our knowledge, hepatocytes should be not susceptible to necroptosis due to the absence of RIPK3 in hepatocytes. However, under a certain condition, MLKL could induce liver cell death in a RIPK3-independent fashion in immune-mediated liver disease. Roychowdhury and his colleagues explored the effect of necroptosis in the different liver models. They found that RIPK3 expression was increased while RIPK1 expression had no change in liver tissues of both humans with ALD and mice after chronic feeding. RIPK3−/− mice had less ethanol-induced steatosis and hepatocyte injury compared to the controls group, but treatment with Nec-1 did not protect against ethanol-induced injury. They also observed that the levels of RIPK3 and MLKL were higher in liver injury in response to high-fat diets. Interestingly, on contrary to the alcohol model, deficiency of RIPK3 could worsen hepatic steatosis, inflammation, and hepatocyte injury. Different from chronic liver injury, studies have found that RIPK1 phosphorylation was induced by acetaminophen in the mouse model of acute liver injury. Treatment with Nec-1 could inhibit reactive oxygen species production in acetaminophen-damaged hepatocytes. Ramachandran and his colleagues found that RIPK3 functioned as an early mediator of acetaminophen-induced hepatocyte necrosis in mice. Inhibiting RIPK3 or using RIPK3-deficient mice could attenuate necrotic cell death. Qian and his colleagues confirmed that mice undergo necroptosis by RIPK1-RIPK3-MLKL pathway upon Listeria monocytogenes infection, subsequently resulting in acute hepatic damage. RIPK1 deletion was found to significantly alleviate mitochondrial dysfunction and necroptosis in Listeria monocytogenes-infected acute liver injury. In previous studies, treating with Nec-1 or MLKL deficiency could protect the liver from Concanavalin A. Taken together, how necroptosis contributes to liver injury pathogenesis remains to be further explored.

2.5 | Acute pancreatitis

Acute pancreatitis (AP) is a local inflammatory disease of the pancreas with multiple causes. The role of necroptosis in the pathophysiology of pancreatitis appears to be controversial because differences in the contribution of necroptosis to the AP have been reported. Inhibition of Nec-1 or knockout of either RIPK3 or MLKL exhibited a reduction in cell death in the pancreas on induction of pancreatitis. In contrast, Boonchan et al. found that RIPK3- or MLKL-deficient mice experienced more severe pancreatic edema and inflammation than control mice. It suggests that necroptosis mediated by RIPK3 and MLKL have a protective effect on AP, whether to use inhibitors of necroptosis requires careful consideration for AP treatment.

2.6 | Enteric diseases

2.6.1 | Necrotizing enterocolitis

NEC is the leading cause of death to gastrointestinal disease in premature infants, which can have devastating effects. Researchers have shown that necroptosis pathway genes, including RIPK1, RIPK3, and MLKL, were significantly upregulated in both NEC patients tissue and established mouse model of NEC. Upregulation of necroptosis is positively correlated with the degree of intestinal damage. Necroptosis inhibition by either genetic or chemical intervention could relieve the intestinal damage, indicating that necroptosis plays an important role in the NEC-induced intestinal damage. Strikingly, the addition of human breast milk oligosaccharide 2 fucosyllactose could reduce necroptosis and inflammation.

2.6.2 | Intestinal injury

Previous studies have shown that damage to the small intestine can be a major contributor to the morbidity and mortality associated with heat stroke. Heat Stress elevated the levels of RIPK1, RIPK3, and phosphorylated MLKL, leading to form the necrosome both in vivo and in vitro. Pretreated with the Nec-1 or GSK872 could significantly reverse these phenomena. These findings provide the basis for developing new therapeutic strategies for patients diagnosed with heat stroke.

2.7 | Renal diseases

2.7.1 | Acute kidney injury

AKI is defined by a rise in serum creatinine, decreased urine output and accumulation of metabolic toxins, resulting in an abrupt reduction in kidney function. Several studies have suggested that inhibition of Nec-1 or deficiency in RIPK3 exerts protective effects in AKI caused by IR injury. Lau A found that RIPK3 deficiency preserved the function of kidney allografts. Similarly, MLKL deficiency was protective against intrinsic renal injury, but not in intrinsic prerenal injury.
2.7.2 Chronic kidney disease

Necroptosis was also found in chronic kidney injury of subtotal nephrectomized rats. Zhu et al. found that necrotic cell death and the highest level of RIPK1 and RIPK3 appeared 8 weeks after subtotal nephrectomy surgery. The renal function and renal pathologic changes improved after administration of Nec-1 and the overexpression of RIPK1, RIPK3, MLKL was reduced. Chen et al. showed that necroptosis of renal proximal tubular cells was activated by RIPK3 and MLKL under the conditions of IRI during AKI to CKD process. Knockdown of RIPK3 or MLKL could attenuate renal tubular cell necroptosis, macrophage infiltration, and then ultimately prevent the progression of interstitial fibrogenesis after IRI.116

2.8 Joint diseases

2.8.1 Rheumatoid arthritis

Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic and systemic inflammation. RA is associated with articular cartilage and bone erosion, synovitis, joint deformity, reduced quality of life, and increased mortality. Necroptosis plays a crucial role in systemic inflammatory response syndrome including RA.117 Chen et al. further confirmed the involvement of necroptosis in articular chondrocytes of the RA model. The expressions of RIPK1, RIPK3, and pMLKL were markedly elevated both in the adjuvant arthritis rat articular cartilage in vivo and in acid-induced chondrocytes in vitro. Treatment with Nec-1 could inhibit chondrocyte necroptosis and prevent articular cartilage damage and reduce the amount of proinflammation cytokine.118 Overall, these results indicate that pharmacological blockade of necroptosis could be a potential therapeutic approach for RA treatment.

2.8.2 Osteoarthritis

OA, the most common degenerative disease characterized by articular cartilage destruction, is caused by mechanical stress, abnormal joint mechanics, and multiple risk factors. According to recent reports, significant accumulation of oxidative stress and cytokine release in OA cartilage, implies a complex relationship between cartilage injury and necroptotic processes.119,120 Cheng et al. found that RIPK1 expression was markedly increased in OA cartilage, both in OA patients and experimental rat models. Upregulation of RIPK1 in articular cartilage could induce structural and functional defects of cartilage in rats, indicating the vital role of RIPK1 in disrupting extracellular matrix metabolism homeostasis and regulating chondrocyte necroptosis during OA progression. The RIPK1 kinase inhibitor (Nec-1) could potently prevent the trauma-induced cartilage degradation and limb pain in rats.121 Consistent with RIPK1, RIPK3 also plays a crucial role in OA pathogenesis. Jeon et al. found that RIPK3 expression was markedly higher in OA-damaged regions of human cartilage than in samples of undamaged cartilage. RIPK3 overexpression could accelerate cartilage disruption in the mouse model, whereas RIPK3 deficiency or inhibition of RIPK3 attenuates OA.122 Altogether, these results provide new insights into the pathogenesis of OA and open new therapeutic avenues for treating OA.

2.9 Cancers

The role of necroptosis in cancer remains controversial because it can be both a tumor suppressor and a tumor promoter.123,124 Necroptosis could induce abnormal cells death leading to a good prognosis, while it could also lead to inflammation and cancer metastasis.125,126 Upregulation and downregulation of major necroptotic members have been observed in many types of cancers. The expression of RIPK1 is generally maintained at a normal level in a variety of cancers, but its expression is upregulated in glioblastoma, lung cancer, and MDS, which has a negative impact on cancer prognosis.125,127–129 In addition to RIPK1, RIPK3 and MLKL are also involved in oncogenesis and related to prognosis. RIPK1/3 or MLKL is downregulated in breast cancer,130,131 colorectal cancer,132–134 melanoma,135 gastric cancer,136 ovarian cancer,137 head and neck squamous cell carcinoma,138 cervical squamous cell carcinoma,139 and AML.140,141 Since necroptosis can function as a tumor suppressor or a tumor promoter, the role of necroptosis in different types of malignant tumors remains to be further studied.

Similarly, necroptosis may be a double-edged sword at different stages of cancer metastasis. The tumor cells spread mostly through the circulatory system to colonize distant organs in the early stage of metastasis. In this process, endothelial cell necroptosis induced by tumor cells could promote extravasation and metastasis.47 Dong et al. has found that depletion of MLKL effectively inhibits invasion of radio-resistant NPC by suppressing epithelial-mesenchymal transition. MLKL may be a promising target to suppress distant metastasis of NPC patients who relapsed after radiotherapy.142 Inhibitors targeting RIPK1 activity could significantly repress metastasis of both lung carcinoma cells and melanoma cells in mice.143 Administration of aurora kinase inhibitor could induce necroptosis and immunogenic cell death, inhibit tumor growth,
and reduce metastasis in mice PANC1 subcutaneous tumor models.\textsuperscript{144} Han et al. found that Resibufogenin could suppress the growth and metastasis of colorectal cancer through induction of RIPK3-dependent necroptosis in vivo.\textsuperscript{145} Thus, further research is urgently required to explore the complex relationship between necroptosis and cancer progression and metastasis.

2.10 | Ocular diseases

2.10.1 | Glaucoma

Glaucoma is a group of chronically progressive diseases of optic nerve, which causes degeneration of retinal ganglion cells (RGC) and peripheral visual field loss. Previous findings have shown that both ischemia and hypoxia could induce necroptosis of RGCs. Nec-1 has an apparent neuroprotective effect on RGC in culture.\textsuperscript{146} In the mouse model of retinal IRI for in vivo and the RGC cell model of oxygen and glucose deprivation for in vitro, Nec-1 could significantly reduce the retinal damage caused by ischemia-reperfusion, increase RGC survival, and attenuate proinflammatory response in the ischemic retina.\textsuperscript{147} In addition to RIPK3, it has been shown that the expression of RIPK3 is rapidly increased in the ganglion cell layer and the inner nuclear layer of the mice retinas following acute increases in intraocular pressure\textsuperscript{148} and ischemia-reperfusion.\textsuperscript{149} These findings indicate that necroptosis appears to be responsible for the development of glaucoma and the inhibition of necroptosis components may be a novel disease therapeutic approach for treating glaucoma.

2.10.2 | Age-related macular degeneration

Age-related macular degeneration (AMD) is a degenerative disease of the macula with visual impairment, which is the leading cause of blindness in the elderly. The etiology of AMD is unclear due to the involvement of numerous factors, among which oxidative stress plays a key role. Researchers have found that retina pigment epithelial (RPE) cells necroptosis is related to RPE cells death under oxidative stress in vitro. Treatment with Nec-1 or down-regulation of RIPK3 by siRNAs could rescue necroptosis induced by oxidative stress. Meanwhile, RPE necroptosis in a retina degeneration mouse model induced by NaIO\textsubscript{3} is also supported by the use of Nec-1.\textsuperscript{150} Jang et al. revealed that RIPK1 inhibitor prevented RPE cells from necroptosis in retinal degeneration in sodium iodate-injected rabbits and iodoacetate acid-treated mini pigs.\textsuperscript{151} Murakami et al. found that RIPK1 and RIPK3 were accumulated in the degenerative retina and RIPK3 deficiency reduced cone cell death.\textsuperscript{152} Collectively, necroptosis is a major form of RPE cell death in response to oxidative stress and it has the potential to provide a novel therapeutic rationale for AMD.

2.11 | Pathogen invasion

2.11.1 | Viral infections

Necroptosis is a host defense mechanism against viral infection.\textsuperscript{153} For example, RIPK3\textsuperscript{−/−} mice infected with vaccinia virus could exhibit severely impaired virus-induced tissue necrosis, inflammation, and control of viral replication.\textsuperscript{5} RIPK3\textsuperscript{−/−} mice were highly susceptible to influenza A virus infection, precisely because RIPK3-deficient macrophages could not produce type I IFN. As a result, the infected mice exhibited elevated pulmonary viral load and heightened morbidity and mortality.\textsuperscript{154} Studies have observed that mice with deficiency of ZBP1 or RIPK3 had high lung virus titers and hypersusceptible to lethal IAV infection.\textsuperscript{154,155} Zhang et al. found that Z-RNAs produced by replicating IAV-activated ZBP1, which activated MLKL to further lead to necroptosis and nuclear envelope rupture in an “inside-out” pathway. MLKL-activated nuclear envelope rupture during IAV infection releases nuclear DAMPs, served as a potent stimulator of neutrophils in cell culture. Consequently, the recruitment and activation of neutrophils is promoted in the infected lung contributing to the severity of IAV disease in vivo.\textsuperscript{156} RIPK3 and its interaction with the herpes simplex virus (HSV)-1 protein ICP6 could trigger the cells necroptosis in infected mouse cells and limit viral propagation in mice.\textsuperscript{157} RIPK3\textsuperscript{−/−} mice infected with West Nile virus exhibited enhanced mortality by suppressing neuronal chemokine expression and decreasing CNS recruitment of T lymphocytes and inflammatory myeloid cells.\textsuperscript{158}

However, it is noteworthy that HIV-1 could induce necroptosis in the infected primary CD4\textsuperscript{+} T lymphocytes and CD4\textsuperscript{+} T-cell lines, leading to the progressive loss of CD4\textsuperscript{+} T cell. Treatment with Nec-1 potently restrained HIV-1-induced cytopathic effect and inhibited the formation of HIV-induced syncytia in CD4\textsuperscript{+} T-cell lines.\textsuperscript{159} Other studies have also confirmed this conclusion through in vivo experiments. Gaiha et al. shows that blockade of necroptosis and silencing of RIPK3 expression could restore the proliferation potential of CD8\textsuperscript{+} T cells from HIV infected patients.\textsuperscript{160} Terahara et al. identified that X4 HIV-1 induced necroptosis characterized by pMLKL expression in CD4\textsuperscript{+} T cells.\textsuperscript{161} Karki et al. found that the combination of TNF-\(\alpha\) and IFN-\(\gamma\) induced inflammatory cell death characterized by pyroptosis, apoptosis, and necroptosis during SARS-CoV-2 infection. TNF-\(\alpha\) and IFN-\(\gamma\) caused a lethal cytokine shock in mice reflecting the
tissue damage and inflammation of COVID-19, and inhibiting necroptosis protected mice from this pathological condition and death. Murine cytomegalovirus (CMV) and HSV encode caspase-8 inhibitors, which could prevent apoptosis together with competitors of RHIM-dependent signal transduction to interrupt the necroptosis. Human CMV blocks TNF-α-induced necroptosis after RIPK3 activation and phosphorylation of the pseudokinase MLKL, which is different from RHIM signaling competition by murine CMV or HSV.

2.11.2 Bacterial infections

Most studies have shown that necroptosis has a detrimental effect on bacterial infections. Necroptosis of immune cells, such as neutrophils and macrophages, induced by Staphylococcus aureus often impeded host defense, leading to tissue damage or even death. Blockage of necroptosis could enhance the clearance of S. aureus, decrease lung tissue injury, and forestall the progression of pneumonia. González-Juarbe et al. proved that various bacterial pathogens, inclusive of Streptococcus marcescens, Listeria monocytogenes, S. aureus, uropathogenic Escherichia coli, Streptococcus pneumonia (SPn), that produce a pore-forming toxin (PFT) induce macrophages necroptosis, which could be blocked for defending toward death by inhibiting of RIPK1, RIPK3, and MLKL. Jondle et al. first reported that Klebsiella pneumonia (KPN) impair the neutrophil efferocytosis through activation of necroptosis pathway improving the disease outcome in vivo in a preclinical mouse model of KPN pneumonia through treatment of KPN-infected mice with Nec-1 or GSK’872 (RIPK3 inhibitor). Interestingly, using a mouse model of SPn asymptomatic colonization, Riegler et al. found that PFT-induced necroptosis contributed to the natural development of protective immunity against opportunistic PFT-producing bacterial pathogens. In human studies, RIPK3 protein concentrations were significantly elevated and were identified as a potential plasma marker of pneumococcal pneumonia. RIPK3-initiated necroptosis is essential for host defense against S. pneumonia. Activation of TLR/TNF signaling during infection, combined with multiple expressions of apoptosis-regulatory proteins, could also promote necroptosis indicating the phosphorylation of MLKL during BMDM infection. It is noteworthy that the inhibition of caspase-8-mediated necroptosis seems to be important to limit excessive inflammatory damage to the host during intestinal Salmonella infection. Enteropathogenic E. coli (EPEC) uses the type III secretion system effector EspL to degrade the RHIM-containing proteins RIPK1, RIPK3, TRIF, and ZBP1/DAI leading to restricting necroptosis and pyroptosis during infection. The highly pathogenic Francisella has been shown to cause necrosis and the highly virulent species of Francisella could induce necroptosis. However, the molecular mechanisms underlying remain to be clarified.

2.11.3 Parasite infections

Rosenberg and Sibley have shown that Toxoplasma gondii effector TgNSM, which targeted NCoR/SMRT complex, antagonizes the interferon to activate necroptosis. This process of T. gondii to prevent the necroptosis contributes to the survival of intracellular cytos and chronic infection. However, there is still uncertainty about the role of necroptosis in parasites killing or control in infected cells. Deletion of RIPK3 could significantly improve survival after oral T. gondii infection but do not increase the parasite burden. Angiostrongylus cantonensis infection might considerably elevate the levels of RIPK3, pRIPK3, and pMLKL, and in vitro assay discovered that TNF-α secretion by activating microglia caused the necroptosis of neurons, providing a new therapeutic strategy for CNS injury.

2.12 Skin diseases

2.12.1 Vitiligo

Vitiligo is a common autoimmune depigmenting skin disorder histologically characterized by the extensive destruction of epidermal melanocytes. Li et al. found that necroptosis was involved in the death of melanocytes through the RIPK1-RIPK3-MLKL pathway under oxidative stress in vitiligo. Accordingly, treatment with Nec-1 or deficient MLKL could enhance the resistance of melanocytes to hydrogen peroxide-induced necroptosis. Thus, targeting necroptosis may provide a new approach to the treatment of vitiligo.

2.12.2 Psoriasis

Psoriasis is an autoimmune skin disorder characterized by hyperproliferation and maturation impairment of keratinocytes. Duan et al. found that MLKL and RIPK1 were markedly expressed in all layers of the epidermis in human psoriasis epidermis. Moreover, pMLKL and RIPK3 were primarily expressed in the upper layers. Inhibition of RIPK1 or MLKL could attenuate necroptosis both in vitro and in vivo, and powerfully reduce inflammation in psoriasiform dermatitis mice induced by IMQ. Therefore,
| Drugs or agentia | Disease | Target | References |
|-----------------|---------|--------|------------|
| Induce          |         |        |            |
| FPK15           | Colorectal cancer cells | RIPK1, RIPK3, and MLKL | 181 |
| ABT737          | Bladder cancer | RIPK3 and MLKL | 184 |
| Smac mimetic BV6| Burkitt’s lymphoma, pancreatic carcinoma | MLKL | 182, 183 |
| Obatoclax       | Different cancers | RIPK1, RIPK3, and MLKL | 185 |
| Interferons     | Different diseases | RIPK3 and MLKL | 186 |
| Ethanol         | Gastric epithelial cells | RIPK1 | 187 |
| Valproic acid   | Epilepsy and mood disorders | RIPK1 | 188 |
| Carbon ion      | Nasopharyngeal carcinoma | MLKL | 189 |
| Decitabine      | Breast cancer | RIPK3 | 190 |
| 5-azacytidine   | Breast cancer | RIPK3 | 190 |
| 5-fluorouracil  | Different cancers | RIPK1 and RIPK3 | 191, 192 |
| Cisplatin       | Different cancers | RIPK1, RIPK3, and MLKL | 193, 194 |
| Anthracyclines  | Lung cancer | RIPK3 and MLKL | 195 |
| Oxaliplatin     | Lung cancer | RIPK3 and MLKL | 195 |
| Tanshinone      | Hepatocellular carcinoma | RIPK1 and RIPK3 | 196 |
| Shikonin        | Pancreatic, osteosarcoma, prostate cancer, and non-small cell lung cancers | RIPK1 and RIPK3 | 197, 198 |
| Emodin          | Renal cancer | RIPK1, RIPK3, and MLKL | 199, 200 |
| Bufalin         | Pancreatic and breast cancers | RIPK1 and RIPK3 | 201 |
| Resibufogenin   | Pancreatic and colorectal cancers | RIPK3 and MLKL | 145 |
| Curcumín        | Prostate carcinoma | RIPK3 and MLKL | 202 |
| Neoaibaconol    | Nasopharyngeal carcinoma | RIPK1 and RIPK3 | 203 |
| Inhibit          |         |        |            |
| Dabrafenib      | Melanoma | RIPK3 | 204 |
| Carfilzomib     | Multiple myeloma | RIPK3 and MLKL | 205 |
| Sorafenib       | Hepatocellular, thyroid, and renal cell cancers | RIPK1 and RIPK3 | 206 |
| Pazopanib       | Renal cell carcinoma and advanced soft tissue sarcoma | RIPK1 | 207 |
| Ponatinib       | Leukemia, ischemic heart injury | RIPK1 and RIPK3 | 208 |
| ZYZ-803         | Acute myocardial ischemia | RIPK3 | 209 |
| Necrostatin-1   | Hypertrophic scars | RIPK1 | 210 |
| GSK2982772      | Rheumatoid arthritis, colitis, and psoriasis | RIPK1 | 211 |
| GSK3145095      | Pancreatic cancer | RIPK1 | 212 |
| Necrosulfonamide | Alzheimer’s Disease, Amyotrophic lateral sclerosis | MLKL | 63, 64 |
| GSK074          | Aortic aneurysms | RIPK1 and RIPK3 | 76 |
| GW806742X       | Asthma | MLKL | 87 |
| SAR443820       | Healthy Subjects | RIPK1 | * |
| SAR443122       | Immune System in Severe COVID-19, Cutaneous Lupus Erythematosus | RIPK1 | * |
| GFH312          | Healthy Subjects | RIPK1 | * |
| Geldanamycin    | Methamphetamine neurotoxicity, Cortical neurons | RIPK3 and MLKL | 216, 217 |
| Geldanamycin    | Pancreatic cancer | RIPK1 | 215 |

(Continues)
### TABLE 3 (Continued)

| Drugs or agentia          | Disease                               | Target                                      | References |
|---------------------------|---------------------------------------|---------------------------------------------|------------|
| Thio-benzoxazepinones     | Cells                                 | RIPK1, RIPK3, and MLKL                      | 218        |
| Bardoxalone derivatives   | Cells                                 | RIPK1 and RIPK3                             | 219        |
| Cyclosporine A            | Immunosuppressive drug                | RIPK1 and RIPK3                             | 213        |
| Rapamycin                 | Restenosis in coronary arteries, retinal detachment, and transplant rejection in lymphangioleiomyomatosis | RIPK1 | 214 |
| Phenytoin                 | Epilepsy and breast cancer            | RIPK1                                       | 184        |
| Chiral benzothiazole      | Cells                                 | RIPK1, RIPK3, and MLKL                      | 220        |
| Aucubin                   | Epilepsy                              | RIPK1 and MLKL                             | 221        |
| Wogonin                   | Acute kidney injury                   | RIPK1                                       | 222        |
| Patchouli alcohol         | Colitis                               | RIPK3 and MLKL                             | 223        |
| Cassia auriculata leaf    | Diabetic nephropathy                  | RIPK1 and RIPK3                             | 224        |

*The website of clinical trials (https://clinicaltrials.gov).*

Inhibiting necroptosis can potentially provide a new target for the treatment of psoriasis.178

### 2.12.3 Stevens–Johnson syndrome and toxic epidermal necrolysis

Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening diseases characterized by the death of keratinocytes. Both apoptosis and necroptosis contribute to keratinocyte death. Abundant RIPK3 and pMLKL expressing keratinocytes could be detected in the epidermis of SJS/TEN skin lesions. Furthermore, the levels of serum RIPK3 were elevated in the acute phase of patients with SJS/TEN. All these results suggested that serum RIPK3 levels could be used as a biomarker of the diagnostic and severity of SJS/TEN.179

### 3 DRUGS AND AGENTS THAT REGULATE NECROPTOSIS

Necroptosis is a very important pattern of cell death. It is not merely involved in the maintenance of organismal homeostasis, but also plays a vital role in the regulation of disease occurrence and development.45 Necroptosis is a double-edged sword in diseases and its development. Researches have shown that inhibiting necroptosis is meaningful for maintaining internal homeostasis and restraining inflammation, ischemia, and toxic syndromes.45,180 Meanwhile, the necroptosis induced by drugs and agents was used as a therapeutic paradigms in the treatment of many tumors. Hence, drugs that inhibit or promote necroptosis may have therapeutic potential for human disease (Table 3).

Several small molecule inhibitors have been reported to induce expression of the key necroptosis molecules including selective 6-phosphofructo-2-kinase (PFKFB3) inhibitor PFK15,181 Smac mimetic BV6,182,183 Bcl-2 inhibitor ABT737,184 and Obatoclax.185 Numerous drugs have also been proved to induced necroptosis, such as interferons,186 ethanol,187 and valproic acid.188 Carbon ion was found to induce the expression of MLKL in nasopharyngeal carcinoma.189 The chemotherapeutic drugs, including Decitabine, 5-azacytidine, 5-fluorouracil, cisplatin, anthracyclines, and oxaliplatin, are critical in cancer therapy by inducing necroptosis.190–195 Moreover, traditional Chinese medicines, such as tanshinone,196 shikonin,197,198 emodin,199,200 bufalin,201 curcumin,202 and resibufogenin,145 also target necroptosis induction in the treatment of different tumors. Neoalbaconol, a naturally occurring small molecule compound, could inhibit the nasopharyngeal carcinoma by inducing necroptosis.203 To sum up, small molecule inhibitors, chemotherapeutic drugs, traditional Chinese medicines drugs, or other agents could be used to treat multiple diseases by inducing necroptosis.

On the contrary, it is also documented that a variety of drugs can downregulate necroptosis including small molecule inhibitors, immunosuppressive drugs, traditional Chinese medicines drugs, and other agents. There were plenty of small molecule inhibitors used in the treatment of multiple diseases or research in healthy subjects such as Dabrafenib,204 Carfilzomib,205 Sorafenib,206 Pazopanib,207 Ponatinib,208 ZYZ-803,209 Nec-1,210 GSK2982772,211 GSK3145095,212 NSA,63,64 GSK074,76 and GW806742X.87 The immunosuppressive drug Cyclosporine A213 and Rapamycin214 were also used to downregulate necroptosis. Several agents, including
### Table 4: Clinical trials related to necroptosis

| Source | Trial number | Conditions                                                                 | Phase               | Interventions                      | Target          |
|--------|--------------|-----------------------------------------------------------------------------|---------------------|------------------------------------|-----------------|
| Clinical Trials | NCT02385331 | Molecular mechanism of neutrophil necroptosis and its roles in RA pathogenesis | Not applicable       | Observational                      | Necroptosis      |
|        | NCT04229992 | Calcium: magnesium balance, microbiota, and Not applicable necroptosis and inflammation | Not applicable       | Magnesium glycinate and placebo     | Necroptosis      |
|        | NCT04169412 | The mortality predictor effect of necroptosis in septic patient              | Not applicable       | Observational                      | RIPK3           |
|        | NCT04549727 | The study the pathophysiology of NEC by using human enteroid biorepository   | Not applicable       | Observational                      | Necroptosis      |
|        | NCT02598648 | Role and molecular mechanism of FXR and RIPK3 in the formation of ARDS in neonates | Not applicable       | Observational                      | RIPK3           |
|        | NCT02965703 | The preventing colorectal carcinoma effect of aspirin in colorectal adenoma patients | 2                   | Aspirin and Placebo                 | MLKL            |
|        | NCT03803774 | The effect of birinapant and IMRT in locally recurrent HNSCC                 | 1                   | Birinapant and IMRT                | MLKL            |
|        | NCT04870125 | The study of safe in ARDS with iCO and placebo                               | 1                   | iCO and placebo                    | RIPK3           |
|        | NCT01105169 | Investigational nutrigenetic studies for cancer prevention                   | Not applicable       | Magnesium glycinate and placebo (MLKL) | MLKL            |
|        | NCT04676711 | A study of GFH312 in healthy subjects                                       | 1                   | GFH312 and placebo                 | RIPK1           |
|        | NCT02776033 | The of safety, tolerability, PK, PD, and efficacy in psoriasis with GSK2982772 | 2                   | GSK2982772 and placebo             | RIPK1           |
|        | NCT02903966 | GSK2982772 study in subjects with ulcerative colitis                        | 2                   | GSK2982772 and placebo             | RIPK1           |
|        | NCT02858492 | The study GSK2982772 in severe RA                                            | 2                   | GSK2982772 and placebo             | RIPK1           |
|        | NCT03266172 | The study of MR, IR, PK, and PD in patients with GSK2982772                 | 1                   | GSK2982772                         | RIPK1           |
|        | NCT03681951 | GSK3145095 alone or combination with Pembrolizumab in advanced solid tumors patients | 2                   | GSK3145095 Pembrolizumab          | RIPK1           |
|        | NCT04982991 | Single ascending dose study of SAR443820 in healthy person in China and Japan | 1                   | SAR443820                          | RIPK1           |
|        | NCT04781816 | Proof of concept study of SAR443122 in patients with CLEan                  | 2                   | SAR443122 and placebo              | RIPK1           |
|        | NCT02903966 | GSK2982772 study in subjects with ulcerative colitis                        | 2                   | GSK2982772 and placebo             | RIPK1           |
|        | NCT04469621 | The safety and effect evaluation of SAR443122 on immune system in severe COVID-19 | 1b                  | SAR443122 and placebo              | RIPK1-RIPK3     |
| CCTR   | ChiCTR2100046488 | Serum RIPK1/RIPK3 levels in patients with acute cerebral infarction       | Not applicable       | Observational                      | RIPK1-RIPK3     |

ARDS, acute respiratory distress syndrome; CCTR, Chinese clinical trial registry; CLEan, Cutaneous Lupus Erythematosus; FXR, Farnesoid X Receptor; HNSCC, head and neck squamous cell carcinoma; IR, immediate release; PK, pharmacokinetics; IMRRT, intensity modulated re-irradiation therapy; MR, modified release; NEC, necrotizing enterocolitis; PD, pharmacodynamics; RA, rheumatoid arthritis.

*All the information is from the websites of clinical trials (https://clinicaltrials.gov/) and Chinese clinical trial registry (http://www.chictr.org.cn).

Geldanamycin, Thio-benzoxazepinones, Bardoxolone derivatives and Chiral benzothiazole could inhibit necroptosis by downregulating the expression of the key molecules. Phenytoin, a clinically used anticonvulsant, could inhibit RIPK1 activity in epilepsy and breast cancer. Moreover, the traditional Chinese medicine drugs could inhibit necroptosis such as aucubin, wogonin, patchouli alcohol, and cassia auriculata leaf extract. In conclusion, drugs and agents that inhibit necroptosis or the expression of RIPK1, RIPK3, and MLKL may have therapeutic potential for human disease.

Nevertheless, most of the drug research on necroptosis has been carried out through in vitro experiments or animal models. Therefore, the clinical feasibility of these
CONCLUSIONS

Necroptosis, as a unique form of cell death, is mediated mainly by RIPK1/RIPK3/MLKL complex, independent of activation of caspase signaling pathway. More and more researches had found that necroptosis is widely involved in biological activities of humans and animals. Clarifying the molecular mechanism of necroptosis and its role in disease and tissue homeostasis is of great significance for harnessing its characteristics to combat disease and maintain homeostasis. The present review summarizes the laboratorial research and clinical applications of inhibitors and inducers of necroptosis pathway including small molecule inhibitors, chemicals, traditional Chinese medicine drugs, biological agents, and other drugs in various pathological conditions. Due to its important role in vital biological activities, the regulation of necroptosis and its key molecules is expected to have broad therapeutic prospects in the fields of health maintenance and disease treatment. However, one concern is that most of the drug research on necroptosis has been carried out through in vitro experiments or animal models, therefore, the clinical feasibility of these compounds and drugs has yet to be evaluated in clinical trials.

ACKNOWLEDGMENTS

This work was supported in part by the Natural Science Foundation of Jiangsu Province (Grants No. BK20190989), Key Research and Development Program of Xuzhou (KC20115), and the 2018 Doctoral Project for Innovation and Entrepreneurship of Jiangsu Province.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ETHICS APPROVAL

No ethical approval was required for this study.

AUTHOR CONTRIBUTION

The contribution of the article confirmed as follows: ZLZ designed the study; analysis, interpretation, and critical revision for important intellectual content were performed by SZY, ZN, LLT, and DX; LXX, XX, and RYY collected the literatures and drafted manuscript. All authors approved the article for publication.

DATA AVAILABILITY STATEMENT

Some or all data, models, or clinical trials or used during the study are available in a repository or online in accordance with funder data retention policies (Provide full citations.)

REFERENCES

1. Laster SM, Wood JG, Gooding LR. Tumor necrosis factor can induce both apoptotic and necrotic forms of cell lysis. J Immunol. 1988;141(8):2629-2634.
2. Vercauteren D, Broeckaert G, Denecker G, et al. Dual signaling of the Fas receptor: initiation of both apoptotic and necrotic cell death pathways. J Exp Med. 1998;188(5):919-930.
3. Holler N, Zaru R, Micheau O, et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol. 2000;1(6):489-495.
4. Degterev A, Huang Z, Boyce M, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2005;1(2):112-119.
5. Cho YS, Challa S, Moquin D, et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell. 2009;137(6):1112-1123.
6. Sun L, Wang H, Wang Z, et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell. 2012;148(1-2):213-227.
7. Zhou W, Yuan J. Necroptosis in health and diseases. Semin Cell Dev Biol. 2014;35:14-23.
8. Quarato G, Guy CS, Grace CR, et al. Sequential engagement of distinct MLKL phosphatidylinositol-binding sites executes necroptosis. Mol Cell. 2016;61(4):589-601.
9. Marshall KD, Baines CP. Necroptosis: is there a role for mitochondria? Front Physiol. 2014;5:323.
10. Declercq W, Vandenameele P. RIP kinases at the crossroads of cell death and survival. Cell. 2009;138(2):229-232.
11. Liu Y, Liu T, Lei T, et al. RIP1/RIP3-regulated necroptosis as a target for multifaceted disease therapy (Review). Int J Mol Med. 2019;44(3):771-786.
12. Zhang S, Tang MB, Luo HY, et al. Necroptosis in neurodegenerative diseases: a potential therapeutic target. Cell Death Dis. 2017;8(6):e2905.
13. Gong Y, Fan Z, Luo G, et al. The role of necroptosis in cancer biology and therapy. Mol Cancer. 2019;18(1):100.
14. Orzalli MH, Kagan JC. Apoptosis and necroptosis as host defense strategies to prevent viral infection. Trends Cell Biol. 2017;27(11):800-809.
15. Tomnus W, Meyer C, Paliege A, et al. The pathological features of regulated necrosis. J Pathol. 2019;247(5):697-707.
16. Grootjans S, Vanden Berghe T, Vandenameele P. Initiation and execution mechanisms of necroptosis: an overview. Cell Death Differ. 2017;24(7):1184-1195.
17. Vandenameele P, Galluzzi L, Vanden Bergh T, et al. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol. 2010;11(10):700-714.
18. Najafov A, Chen H, Yuan J. Necroptosis and cancer. Cell 2017;17(3):294-301.
19. Vanlangenakker N, Vanden Berghe T, Bogaert P, et al. cIAP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1/RIP3-dependent reactive oxygen species production. Cell Death Differ. 2011;18(4):656-665.
20. Schwabe RF, Luedde T. Apoptosis and necroptosis in the liver: a matter of life and death. Nat Rev Gastroenterol Hepatol. 2018;15(12):738-752.
21. Han J, Zhong CQ, Zhang DW. Programmed necrosis: backup to and competitor with apoptosis in the immune system. Nat Immunol. 2011;12(12):1143-1149.
22. Chang L, Kamata H, Solinas G, et al. The E3 ubiquitin ligase Itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell. 2006;124(3):601-613.
23. He S, Huang S, Shen Z. Biomarkers for the detection of necroptosis. Cell Mol Life Sci. 2016;73(11-12):2177-2181.
24. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell. 2003;114(2):181-190.
25. Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell. 2008;133(4):693-703.
26. Dondelinger Y, Jouan-Lanhouet S, Divert T, et al. NF-κB-independent role of IKKe/IKKδ in preventing RIPK1 kinase-dependent apoptotic and necrotic cell death during TNF signaling. Mol Cell. 2015;60(1):63-76.
27. Mompeán M, Li W, Li J, et al. The structure of the necrosome RIPK1-RIPK3 core, a human hetero-amyloid signaling complex. Cell. 2018;173(5):1244-1253.
28. Wang Z, Feng J, Yu J, et al. FKBP12 mediates necroptosis by recruiting RIPK1/FADD/RIPK3 signaling to TNF receptor 1 ligation. J Cell Sci. 2019;132(10):jcs227777.
29. Jia MM, Li YQ, Xu KQ, et al. Jujuboside B promotes the death of acute leukemia cell in a RIPK1/RIPK3/MLKL pathway-dependent manner. Eur J Pharmacol. 2020;876:173041.
30. Geserick P, Hupe M, Moulin M, et al. Cellular IAPs inhibit a cryptic CD95-induced cell death by limiting RIP1 kinase recruitment. J Cell Biol. 2009;187(7):1037-1054.
31. Olengeim D, Yuan J. Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death. Nat Rev Mol Cell Biol. 2013;14(11):727-736.
32. Zhang C, Luo Y, He Q, et al. A pan-RAF inhibitor LY3009120 inhibits necroptosis by preventing phosphorylation of RIP1 and alleviates dextran sulfate sodium-induced colitis. Clin Sci (Lond). 2019;133(8):919-932.
33. Zhang T, Zhang Y, Cui M, et al. CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress-induced myocardial necroptosis. Nat Med. 2016;22(2):175-182.
34. Hu H, Wu X, Wu G, et al. RIP3-mediated necroptosis is regulated by inter-filament assembly of RIP homotypic interaction motif. Cell Death Differ. 2021;28(1):251-266.
35. Kaiser WJ, Sridharan H, Huang C, et al. Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J Biol Chem. 2013;288(45):31268-31279.
36. Guo H, Omoto S, Harris PA, et al. Herpes simplex virus suppresses necroptosis in human cells. Cell Host Microbe. 2015;17(2):243-251.
37. Yu X, Li Y, Chen Q, et al. Herpes simplex virus 1 (HSV-1) and HSV-2 mediate species-specific modulations of programmed necrosis through the viral ribonucleotide reductase large subunit R1. J Virol. 2016;90(2):1088-1095.
38. Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of the human genome. Science. 2002;298(5600):1912-1934.
39. Zhang Y, Liu J, Yu D, et al. The MLKL kinase-like domain dimerization is an indispensable step of mammalian MLKL activation in necroptosis signaling. Cell Death Dis. 2021;12(7):638.
40. Wang H, Sun L, Su L, et al. Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Mol Cell. 2014;54(1):133-146.
41. Zhan C, Huang M, Yang X, et al. MLKL: functions beyond serine as the executor of necroptosis. Theranostics. 2021;11(10):4759-4769.
42. Martens S, Bridelance J, Roelandt R, et al. MLKL in cancer: more than a necroptosis regulator. Cell Death Differ. 2021;28(6):1757-1772.
43. Newton K. RIPK1 and RIPK3: critical regulators of inflammation and cell death. Trends Cell Biol. 2015;25(6):347-353.
44. Schwarzer R, Laurien L, Pasparakis M. New insights into the regulation of apoptosis, necroptosis, and pyroptosis by receptor interacting protein kinase 1 and caspase-8. Curr Opin Cell Biol. 2020;63:186-193.
45. Kondylis V, Kumari S, Vlantis K, et al. The interplay of IKK, NF-κB and RIPK1 signaling in the regulation of cell death, tissue homeostasis and inflammation. Immunol Rev. 2017;277(1):113-127.
46. Li J, Ke X, Yan F, et al. Necroptosis in the periodontal homeostasis: signals emanating from dying cells. Oral Dis. 2018;24(6):900-907.
47. Strillic B, Yang L, Albarrán-Juárez J, et al. Tumour-cell-induced endothelial cell necroptosis via death receptor 6 promotes metastasis. Nature. 2016;536(7615):215-218.
48. Liu ZY, Wu B, Guo YS, et al. Necrostatin-1 reduces intestinal inflammation and colitis-associated tumorigenesis in mice. Am J Cancer Res. 2015;5(10):3174-3185.
49. Zhao H, Zhou M, Hu Y, et al. TNF-α triggers RIP1/FADD/Caspase-8-mediated apoptosis of astrocytes and RIP3/MLKL-mediated necroptosis of neurons induced by Angiostrongylus cantonensis infection. Cell Mol Neurobiol. 2021.
50. Roychowdhury S, McMullen MR, Pisano SG, et al. Absence of receptor interacting protein kinase 3 prevents ethanol-induced liver injury. Hepatology. 2013;57(5):1773-1783.
51. Lu Z, Van Eechoutte HP, Liu G, et al. Necroptosis signaling promotes inflammation, airway remodeling, and emphysema in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2021;204(6):667-681.
52. Chen J, Wang S, Fu R, et al. RIP3 dependent NLRP3 inflammasome activation is implicated in acute lung injury in mice. J Transl Med. 2018;16(1):233.
53. Chen H, Fang Y, Wu J, et al. RIPK3-MLKL-mediated necroinflammation contributes to AKI progression to CKD. Cell Death Dis. 2018;9(9):878.
54. Werts AD, Fulton WB, Ladd MR, et al. A novel role for necroptosis in the pathogenesis of necrotizing enterocolitis. Cell Mol Gastroenterol Hepatol. 2020;9(3):403-423.
55. Newton K, Dugger DL, Maltzman A, et al. RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than
MLKL deficiency in mouse models of inflammation and tissue injury. Cell Death Differ. 2016;23(9):1565-1576.
56. Zhang Y, Li M, Li X, et al. Catalytically inactive RIP1 and RIP3 deficiency protect against acute ischemic stroke by inhibiting necroptosis and neuroinflammation. Cell Death Dis. 2020;11(7):565.
57. Yang J, Zhao Y, Zhang L, et al. RIPK3/MLKL-mediated neuronal necroptosis modulates the M1/M2 polarization of microglia/macrophages in the ischemic cortex. Cereb Cortex. 2018;28(7):2622-2635.
58. Iannielli A, Bido S, Folladori L, et al. Pharmacological inhibition of necroptosis protects from dopaminergic neuronal cell death in Parkinson’s disease models. Cell Rep. 2018;22(8):2066-2079.
59. Wu JR, Wang J, Zhou SK, et al. Necrostatin-1 protection of dopaminergic neurons. Neural Regen Res. 2015;10(7):1120-1124.
60. Ofate M, Catenaccio A, Salvadores N, et al. The necroptosis machinery mediates axonal degeneration in a model of Parkinson disease. Cell Death Differ. 2020;27(4):1169-1185.
61. Caccamo A, Branca C, Piras IS, et al. Necroptosis activation in Alzheimer’s disease. Nat Neurosci. 2017;20(9):1236-1246.
62. Ofengeim D, Mazzitelli S, Ito Y, et al. RIPK1 mediates a disease-associated microglial response in Alzheimer’s disease. Proc Natl Acad Sci USA. 2017;114(41):E8788-E8797.
63. Motawi TMK, Abdel-Nasser ZM, Shahin NN. Ameliorative effect of nercosulfonamide in a rat model of Alzheimer’s disease: targeting mixed lineage kinase-domain-like protein-mediated necroptosis. ACS Chem Neurosci. 2020;11(20):3386-3397.
64. Re DB, Le Verche V, Yu C, et al. Necroptosis drives motor neuron death in models of both sporadic and familial ALS. Neuron. 2014;81(5):1001-1008.
65. Ito Y, Ofengeim D, Najafov A, et al. RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS. Science. 2016;353(6299):603-608.
66. Ofengeim D, Ito Y, Najafov A, et al. Activation of necroptosis in multiple sclerosis. Cell Rep. 2015;10(1):1836-1849.
67. Picon C, Jayaraman A, James R, et al. Neuron-specific activation of necroptosis signaling in multiple sclerosis cortical grey matter. Acta Neuropathol. 2021;141(4):585-604.
68. Zhang S, Su Y, Ying Z, et al. RIP1 kinase inhibitor halts the progression of an immune-induced demyelination disease at the stage of monocyte elevation. Proc Natl Acad Sci USA. 2019;116(12):5675-5680.
69. Lu AR, Kim TH, Park SJ, et al. Mitochondrial damage and necroptosis in aging cochlea. Int J Mol Sci. 2020;21(7):2505.
70. Luedde M, Lutz M, Carter N, et al. RIP3, a kinase promoting necrotic cell death, mediates adverse remodelling after myocardial infarction. Cardiovasc Res. 2014;103(2):206-216.
71. Smith CC, Davidson SM, Lim SY, et al. Necrostatin: a potentially novel cardioprotective agent? Cardiovasc Drugs Ther. 2007;21(4):227-233.
72. Oerlemans MI, Liu J, Arslan F, et al. Inhibition of RIP1-dependent necrosis prevents adverse cardiac remodeling after myocardial ischemia-reperfusion in vivo. Basic Res Cardiol. 2012;107(4):270.
73. Dmitriev YV, Minasian SM, Demchenko EA, et al. Study of cardioprotective effects of necroptosis inhibitors on isolated rat heart subjected to global ischemia-reperfusion. Bull Exp Biol Med. 2013;155(2):245-248.
74. Wang Q, Liu Z, Ren J, et al. Receptor-interacting protein kinase 3 contributes to abdominal aortic aneurysms via smooth muscle cell necrosis and inflammation. Circ Res. 2015;116(4):600-611.
75. Wang Q, Zhou T, Liu Z, et al. Inhibition of receptor-interacting protein kinase 1 with necrostatin-1 ameliorates disease progression in elastase-induced mouse abdominal aortic aneurysm model. Sci Rep. 2017;7:42159.
76. Zhou T, Wang Q, Pan N, et al. Identification of a novel class of RIP1/RIP3 dual inhibitors that impede cell death and inflammation in mouse abdominal aortic aneurysm models. Cell Death Dis. 2019;10(3):226.
77. Karunakaran D, Geoffrion M, Wei L, et al. Targeting macrophage necroptosis for therapeutic and diagnostic interventions in atherosclerosis. Sci Adv. 2016;2(7):e1600224.
78. Chen Y, Li X, Hua Y, et al. RIPK3-mediated necroptosis in diabetic cardiomyopathy requires CaMKII activation. Oxid Med Cell Longev. 2021;2021:6617816.
79. Labaki WW, Rosenberg SR. Chronic obstructive pulmonary disease. Ann Intern Med. 2020;173(3):Itc17-32.
80. Mizumura K, Cloonan SM, Nakahira K, et al. Mitophagy-dependent necroptosis contributes to the pathogenesis of COPD. J Clin Invest. 2014;124(9):3987-4003.
81. Pouwels SD, Zijlstra GJ, van der Toorn M, et al. Cigarette smoke-induced necroptosis and DAMP release trigger neutrophilic airway inflammation in mice. Am J Physiol Lung Cell Mol Physiol. 2016;310(4):L377-386.
82. Pan L, Yao DC, Yu YZ, et al. Activation of necroptosis in a rat model of acute respiratory distress syndrome induced by oleic acid. Sheng Li Xue Bao. 2016;68(5):661-668.
83. Pan L, Yao DC, Yu YZ, et al. Necrostatin-1 protects against oleic acid-induced acute respiratory distress syndrome in rats. Biochem Biophys Res Commun. 2016;478(4):1602-1608.
84. Wang L, Wang T, Li H, et al. Receptor interacting protein 3-mediated necroptosis promotes lipopolysaccharide-induced inflammation and acute respiratory distress syndrome in mice. PLoS One. 2016;11(5):e0155723.
85. Cevhertas L, Ogulur I, Maurer DJ, et al. Advances and recent developments in asthma in 2020. Allergy. 2020;75(12):3124-3146.
86. Radonjcic-Hoesli S, Wang X, de Graauw E, et al. Adhesion-induced eosinophil cytolsis requires the receptor-interacting protein kinase 3 (RIPK3)-mixed lineage kinase-like (MLKL) signaling pathway, which is counterregulated by autophagy. J Allergy Clin Immunol. 2017;140(6):1632-1642.
87. Shlomovitz I, Erelch Z, Speir M, et al. Necroptosis directly induces the release of full-length biologically active IL-33 in vitro and in an inflammatory disease model. FEBs J. 2019;286(3):507-522.
88. Cerps SC, Menzel M, Mahmutovic Persson I, et al. Interferon-β deficiency at asthma exacerbation promotes MLKL mediated necroptosis. Sci Rep. 2018;8(1):4248.
89. Zhao Y, Zhang H, Yang X, et al. Fine particulate matter (PM2.5) enhances airway hyperresponsiveness (AHK) by inducing necroptosis in BALB/c mice. Environ Toxicol Pharmacol. 2019;68:155-163.
90. Simpson J, Loh Z, Ullah MA, et al. Respiratory syncytial virus infection promotes necroptosis and HMGB1 release by airway
epithelial cells. *Am J Respir Crit Care Med.* 2020;201(11):1358-1371.

91. Lee JM, Yoshida M, Kim MS, et al. Involvement of alveolar epithelial cell necroptosis in idiopathic pulmonary fibrosis pathogenesis. *Am J Respir Cell Mol Biol.* 2018;59(2):215-224.

92. Syed MA, Shah D, Das P, et al. TREM-1 attenuates RIPK3-mediated necroptosis in hyperoxia-induced lung injury in neonatal mice. *Am J Respir Cell Mol Biol.* 2019;60(3):308-322.

93. Siempos II, Ma KC, Imamura M, et al. RIPK3 mediates pathogenesis of experimental ventilator-induced lung injury. *JCI Insight.* 2018;3(9):e97102.

94. Bolognese AC, Yang WL, Hansen LW, et al. Inhibition of αRIP1-and RIP3-mediated necroptosis in tumour necrosis factor-α-mediated acute liver injury and inflammatory response induced by *Listeria monocytogenes*. *FEBS Open Bio.* 2016;6(4):2099-2108.

95. Hildebrand JM, Tanzer MC, Lucket IS, et al. Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necrotic cell death. *Proc Natl Acad Sci USA.* 2014;111(42):15072-15077.

96. Murphy JM, Vince JE. Post-translational control of RIPK3 and MLKL mediated necroptotic cell death. *FL1000Res.* 2015;4:F1000.

97. Duan PY, Ma Y, Li XN, et al. Inhibition of RIPK1-dependent necroptosis attenuates lung injury and improves survival in neonatal sepsis. *Surgery.* 2018;S0039-6060(18):30096-30105.

98. Wang FS, Fan JG, Zhang Z, et al. The global burden of liver disease: the major impact of China. *Hepatology.* 2014;60(6):2099-2108.

99. Degterev A, Zhou W, Maki JL, et al. Assays for necroptosis and activity of RIP Kinas. *Methods Enzymol.* 2014;545:1-33.

100. Roychowdhury S, McCullough RL, Sanz-Garcia C, et al. Receptor interacting protein 3 protects mice from high-fat diet-induced liver injury. *Hepatology.* 2016;64(5):1518-1533.

101. Takemoto K, Hatano E, Iwaisako K, et al. Necrostatin-1 protects the molecular mechanism of αRIP1-and RIP3-mediated necroptosis in hyperoxia-induced lung injury of subtotal nephrectomised rats. *Biochem Biophys Res Commun.* 2015;461(4):575-580.

102. Stolberg-Stolberg J, Sambale M, Hansen U, et al. Cartilage proteoglycan degradation accelerates osteoarthritis pathogenesis. *Int J Mol Sci.* 2018;19(12):343-358.

103. Linkermann A, De Zen F, Weinberg J, et al. Programmed necrosis in acute kidney injury. *Cell Death Dis.* 2012;3(9):e3412-3419.

104. Boonchuan M, Arimochi H, Otsuka K, et al. Cancer therapy in the necroptosis era. *Tumour Biol.* 2017;39(6):1010428317711539.

105. Liu ZG, Jiao D. Necroptosis, tumornecrosis and tumorigenesis. *Cell Mol Gastroenterol Hepatol.* 2014;60(6):2099-2108.

106. He S, Wang L, Miao L, et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. *Cell.* 2009;137(6):1100-1111.

107. Linkermann A, Bräsen JH, De Zen F, et al. Dichotomy between RIP1- and RIP3-mediated necroptosis in tumor necrosis factor-α-induced shock. *Mol Med.* 2012;18(1):577-586.

108. Wu J, Huang Z, Ren J, et al. Mlkl knockout mice demonstrate the indispensable role of Mlkl in necroptosis. *Cell Res.* 2013;23(8):994-1006.

109. Louhimo J, Steer ML, Perides G. Necroptosis is an important severity determinant and potential therapeutic target in experimental severe pancreatitis. *Cell Mol Gastroenterol Hepatol.* 2016;2(4):519-535.

110. Duan FY, Ma Y, Li XM, et al. Inhibition of RIPK1-dependent regulated acinar cell necrosis provides protection against acute pancreatitis via the RIPK1/NF-κB/AQP8 pathway. *Exp Mol Med.* 2019;51(8):1-17.

111. Boonchuan M, Arimochi H, Otsuka K, et al. Necroptosis protects against exacerbation of acute pancreatitis. *Cell Death Dis.* 2012;12(6):601.

112. Li L, Tan H, Zou Z, et al. Preventing necroptosis by scavenging ROS production alleviates heat-stress-induced intestinal injury. *Int J Hyperthermia.* 2020;37(1):517-530.

113. Linkermann A, De Zen F, Weinberg J, et al. Programmed necrosis in acute kidney injury. *Nephrol Dial Transplant.* 2012;27(9):3412-3419.

114. Linkermann A, Bräsen JH, Darding M, et al. Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury. *Proc Natl Acad Sci USA.* 2013;110(29):12024-12029.

115. Lau A, Wang S, Jiang J, et al. RIPK3-mediated necroptosis promotes donor kidney inflammatory injury and reduces allograft survival. *Am J Transplant.* 2013;13(11):2805-2818.

116. Zhu Y, Cui H, Gan H, et al. Necroptosis mediated by receptor interaction protein kinase 1 and 3 aggravates chronic kidney injury of subtotal nephrectomised rats. *Biochem Biophys Res Commun.* 2015;461(4):575-581.

117. Lee SH, Kwon JY, Kim SY, et al. Interferon-γamma regulates inflammatory cell death by targeting necroptosis in experimental autoimmune arthritis. *Sci Rep.* 2017;7(1):10133.

118. Chen Y, Zhu CJ, Zhu F, et al. Necrostatin-1 ameliorates adjuvant arthritis rat articular chondrocyte injury via inhibiting ASIC1a-mediated necroptosis. *Biochem Biophys Res Commun.* 2018;504(4):843-850.

119. Rieger J, Brenner RE. Evidence of necroptosis in osteoarthritis disease: investigation of blunt mechanical impact as possible trigger in regulated necrosis. *Cell Death Dis.* 2019;10(10):683.

120. Stolberg-Stolberg J, Sambale M, Hansen U, et al. Cartilage trauma induces necrotic chondrocyte death and expulsion of cellular contents. *Int J Mol Sci.* 2020;21(12):4204.

121. Cheng J, Duan X, Fu X, et al. RIP1 perturbation induces chondrocyte necroptosis and promotes osteoarthritis pathogenesis via targeting BMP7. *Front Cell Dev Biol.* 2021;9:638382.

122. Jeon J, Noh HJ, Lee H, et al. TRIM24-RIP3 axis perturbs donorkidney inflammatory injury and reduces allograft survival. *Am J Transplant.* 2013;13(11):2805-2818.

123. Liu ZG, Jiao D. Necroptosis, tumor necrosis and tumorigenesis. *Cell Stress.* 2019;4(1):1-8.

124. Zhu F, Zhang W, Yang T, et al. Complex roles of necroptosis in cancer. *J Zhejiang Univ Sci B.* 2019;20(5):399-413.

125. Wang T, Jin Y, Yang W, et al. Necroptosis in cancer: an angel or a demon? *Tumour Biol.* 2017;39(6):101042831771539.

126. Su Z, Yang Z, Xie L, et al. Cancer therapy in the necroptosis era. *Cell Death Differ.* 2016;23(5):748-756.

127. Park S, Hatanpaa KJ, Xie Y, et al. The receptor interacting protein 1 inhibits p53 induction through NF-κB activation and confers a worse prognosis in glioblastoma. *Cancer Res.* 2009;69(7):2809-2816.
128. Wang Q, Chen W, Xu X, et al. RIP1 potentiates BPDE-induced transformation in human bronchial epithelial cells through catalase-mediated suppression of excessive reactive oxygen species. *Carcinogenesis*. 2013;34(9):2119-2128.

129. Montalban-Bravo G, Class CA, Ganan-Gomez I, et al. Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes. *Leukemia*. 2020;34(3):872-881.

130. Stoll G, Ma Y, Yang H, et al. Pro-necrotic molecules impact local immunosurveillance in human breast cancer. *Oncoimmunology*. 2017;6(4):e1299302.

131. Won KY, Min SY, Song JY, et al. Clinical significance of receptor-interacting protein 3 and parkin, essential molecules for necroptosis, in breast cancer. *J Breast Cancer*. 2021;24(1):34-48.

132. Feng X, Song Q, Yu A, et al. Receptor-interacting protein kinase 3 is a predictor of survival and plays a tumor suppressive role in colorectal cancer. *Neoplasma*. 2015;62(4):592-601.

133. Conev NV, Dimitrova EG, Bogdanova MK, et al. RIPK3 expression as a potential predictive and prognostic marker in metastatic colon cancer. *Clin Invest Med*. 2019;42(1):E31-E38.

134. Li X, Guo J, Ding AP, et al. Association of mixed lineage kinase domain-like protein expression with prognosis in patients with colon cancer. *Technol Cancer Res Treat*. 2017;16(4):428-434.

135. Geserick P, Wang J, Schilling R, et al. Absence of RIPK3 predicts necroptosis resistance in malignant melanoma. *Cell Death Dis*. 2015;6(9):e1884.

136. Ertao Z, Jianhui C, Kang W, et al. Prognostic value of mixed lineage kinase domain-like protein expression in the survival of patients with gastric cancer. *Tumour Biol*. 2016;37(10):13679-13685.

137. He L, Peng K, Liu Y, et al. Low expression of mixed lineage kinase domain-like protein is associated with poor prognosis in ovarian cancer patients. *Onco Targets Ther*. 2013;6:1539-1543.

138. McCormick KD, Ghosh A, Trivedi S, et al. Innate immune signaling through differential RIPK1 expression promote tumor progression in head and neck squamous cell carcinoma. *Carcinogenesis*. 2016;37(5):522-529.

139. Ruan J, Mei L, Zhu Q, et al. Mixed lineage kinase domain-like protein is a prognostic biomarker for cervical squamous cell cancer. *Int J Clin Exp Pathol*. 2015;8(11):15035-15038.

140. Nogusa S, Thapa RJ, Dillon CP, et al. RIPK3 activates paralineage necrosis in ovarian cancer patients. *PLoS Pathog*. 2017;13(4):e1006326.

141. Huang JF, Shang L, Zhang MQ, et al. Differential expression of RIP1-RIP3 binding to HSV-1 ICP6 initiates necroptosis to restrict virus propagation in mice. *Cell Death Discov*. 2019;5:60.

142. Höckendorf U, El Bouazzati H, Hétuin D, et al. RIP3 is downregulated in human myeloid leukemia cells and modulates apoptosis and caspase-mediated p65/RelA cleavage. *Cell Death Dis*. 2014;5(8):e1384.

143. Höckendorf U, Yabal M, Herold T, et al. RIPK3 restricts myeloid leukemogenesis by promoting cell death and differentiation of leukemia initiating cells. *Cancer Cell*. 2016;30(1):75-91.

144. Dong Y, Sun Y, Huang Y, et al. Depletion of MLKL inhibits invasion of radioresistant nasopharyngeal carcinoma cells by suppressing epithelial-mesenchymal transition. *Ann Transl Med*. 2019;7(23):741.

145. Hou J, Ji J, Zhang Z, et al. Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis. *Cell Death Dis*. 2019;10(7):493.

146. Xie Y, Zhu S, Zhong M, et al. Inhibition of aurora kinase A induces necroptosis in pancreatic carcinoma. *Gastroenterology*. 2017;153(5):1429-1443.

147. Han Q, Ma Y, Wang H, et al. Resibufogenin suppresses colorectal cancer growth and metastasis through RIP3-mediated necroptosis. *J Transl Med*. 2018;16(1):201.

148. Thomas CN, Thompson AM, Ahmed Z, et al. Retinal ganglion cells die by necroptotic mechanisms in a site-specific manner in a rat blunt ocular injury model. *Cells*. 2019;8(12):1517.

149. Dvoriantchikova G, Degterev A, Ivanov D. Retinal ganglion cell (RGC) programmed necrosis contributes to ischemia-reperfusion-induced retinal damage. *Exp Eye Res*. 2014;123:1-7.

150. Huang JF, Shang L, Zhang MQ, et al. Differential neuronal expression of receptor interacting protein 3 in rat retina: involvement in ischemic stress response. *BMC Neurosci*. 2013;14:16.

151. Shosha E, Xu Z, Yokota H, et al. Arginase 2 promotes neurovascular degeneration during ischemia/reperfusion injury. *Cell Death Dis*. 2016;7(11):e2483.

152. Hansu J, Anderson C, Sarraf D, et al. Retinal pigmented epithelial cell necroptosis in response to sodium iodate. *Cell Death Discov*. 2016;2:16054.

153. Hong KH, Do YJ, Koo TS, et al. Protective effect of RIPK1-inhibitory compound in vivo models for retinal degenerative disease. *Exp Eye Res*. 2019;180:8-17.

154. Murakami Y, Matsumoto H, Roh M, et al. Receptor interacting protein kinase mediates necrotic cone but not rod cell death in a mouse model of inherited degeneration. *Proc Natl Acad Sci USA*. 2012;109(36):14598-14603.

155. Pasparakis M, Vandenabeele P. Necroptosis and its role in inflammation. *Nature*. 2015;517(7534):311-320.

156. Downey J, Pernet E, Coulombe F, et al. RIPK3 interacts with MAVS to regulate type I IFN-mediated immunity to Influenza A virus infection. *Cell Death Discov*. 2017;3(4):e1006326.

157. Huang Z, Wu SQ, Liang Y, et al. RIP1/RIP3 binding to HSV-1 ICP6 initiates necroptosis to restrict virus propagation in mice. *Cell Death Dis*. 2015;6:229-242.

158. Daniels BP, Snyder AG, Olsen TM, et al. RIPK3 activates parallel pathways of MLKL-driven necroptosis and FADD-mediated apoptosis to protect against influenza A virus. *Cell Host Microbe*. 2016;20(1):13-24.

159. Zhang T, Yin C, Boyd DF, et al. Influenza virus Z-RNAs induce ZBP1-mediated necrosis. *Cell*. 2020;180(6):1115-1129.

160. Huang Z, Wu SQ, Liang Y, et al. RIP1/RIP3 binding to HSV-1 ICP6 initiates necroptosis to restrict virus propagation in mice. *Cell Death Dis*. 2015;6:229-242.

161. Daniels BP, Snyder AG, Olsen TM, et al. RIPK3 restricts viral pathogenesis via cell death-independent neuroinflammation. *Cell*. 2017;169(2):301-313.e311.

162. Pan T, Wu S, He X, et al. Necroptosis takes place in human immunodeficiency virus type-1 (HIV-1)-infected CD4+ T lymphocytes. *PLoS One*. 2014;9(4):e93944.

163. Gaih GM, McKim KJ, Woods M, et al. Dysfunctional HIV-specific CD8+ T cell proliferation is associated with increased caspase-8 activity and mediated by necroptosis. *Immunity*. 2014;41(6):1001-1012.

164. Terahara K, Iwabuchi R, Iwaki R, et al. Substantial induction of non-apoptotic CD4 T-cell death during the early phase of HIV-1 infection in a humanized mouse model. *Microbes Infect*. 2015;17(2):229-242.

165. Karki R, Sharma BR, Tuladhar S, et al. Synergism of TNF-α and IFN-γ triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. *Cell*. 2021;184(1):149-168.
163. Omoto S, Guo H, Talekar GR, et al. Suppression of RIP3-dependent necroptosis by human cytomegalovirus. *J Biol Chem*. 2015;290(18):11635-11648.

164. Paudel S, Ghimire L, Jin L, et al. NLRC4 suppresses IL-17A-mediated neutrophil-dependent host defense through upregulation of IL-18 and induction of necroptosis during Gram-positive pneumonia. *Mucosal Immunol*. 2019;12(1):247-257.

165. Zhou Y, Niu C, Ma B, et al. Inhibiting PSMs-induced neutrophil necroptosis protects mice with MRSA pneumonia by blocking the AGR system. *Cell Death Dis*. 2018;9(3):362.

166. González-Juarbe N, Gilley RP, Hinojosa CA, et al. Pore-forming toxins induce macrophage necroptosis during acute bacterial pneumonia. *PLoS Pathog*. 2015;11(12):e1005337.

167. Jondle CN, Gupta K, Mishra BB, et al. Klebsiella pneumoniae infection of murine neutrophils impairs their efferocytic clearance by modulating cell death machinery. *PLoS Pathog*. 2018;14(10):e1007338.

168. Riegler AN, Brissac T, Gonzalez-Juarbe N, et al. Necroptotic cell death promotes adaptive immunity against colonizing pneumococci. *Front Immunol*. 2019;10:615.

169. Huang HR, Cho SJ, Harris RM, et al. RIPK3 activates MLKL-mediated necroptosis and inamasosme signaling during streptococcus infection. *Am J Respir Cell Mol Biol*. 2021;64(5):579-591.

170. Christgen S, Zheng M, Kesavardhana S, et al. Identification of the PANoptosome: a molecular platform triggering pyroptosis, apoptosis, and necroptosis (PANoptosis). *Front Cell Infect Microbiol*. 2020;10:237.

171. Hos NJ, Ganesan R, Gutiérrez S, et al. Type I interferon sensitivity of *Salmonella Typhimurium*-infected macrophages by impairing antioxidative stress responses. *J Cell Biol*. 2017;216(12):4107-4121.

172. Hefele M, Stolzer I, Ruder B, et al. Inhibiting PSM-mediated neutrophi necroptosis pathway blockage of AGR system. *Cell Death Dis*. 2019;25(6):707-725.

173. Pearson JS, Giogha C, Mühlen S, et al. EspL is a bacterial cytosine protease effector that cleaves RHIM proteins to block necroptosis and inflammation. *Nat Microbiol*. 2017;2:16258.

174. Kesavardhana S, Kuriakose T, Guy CS, et al. ZBP1/DAI ubiquitination cell death during streptococcus infection. *Mucosal Immunol*. 2018;11(4):1191-1202.

175. Rosenberg A, Sibley LD. Toxoplasma gondii secreted effectors co-opt host repressor complexes to inhibit necroptosis. *Cell Host Microbe*. 2021;29(7):e1188.

176. Cervantes PW, Martorelli Di Genova B, Erazo Flores BJ, et al. RIPK3 facilitates host resistance to oral *Toxoplasma gondii* infection. *Infect Immun*. 2021;89(5):e00021.

177. Li B, Yi X, Zhuang T, et al. RIP1-mediated necroptosis facilitates oxidative stress-mediated melanocyte death, offering insight into vitiligo. *J Invest Dermatol*. 2021;141:2921-2931.

178. Duan X, Liu X, Liu N, et al. Inhibition of keratinocyte necroptosis mediated by RIPK1/RIPK3/MLKL provides a protective effect against psoriatic inflammation. *Cell Death Dis*. 2020;11(2):134.

179. Hasegawa A, Shinkuma S, Hayashi R, et al. RIP3 as a diagnostic and severity marker for Stevens–Johnson syndrome and toxic epidermal necrolysis. *J Allergy Clin Immunol Pract*. 2020;8(5):1768-1771.

180. Deng XX, Li SS, Sun FY. Necrostatin-1 prevents necroptosis in brains after ischemic stroke via inhibition of RIPK1-mediated RIPK3/MLKL signaling. *Aging Dis*. 2019;10(4):807-817.

181. Yan S, Li Q, Zhang D, et al. Necroptosis pathway blockage attenuates PFKFB3 inhibitor-induced cell viability loss and genome instability in colorectal cancer cells. *Am J Cancer Res*. 2021;11(5):2062-2080.

182. Koch A, Jeiler B, Roedig J, et al. SMAC mimetics and TRAIL cooperate to induce MLKL-dependent necroptosis in Burkitt’s lymphoma cell lines. *Neoplasia*. 2021;23(5):539-550.

183. Hannes S, Karlowitz R, van Wijk SJL. The Smac mimetic BV6 cooperates with STING to induce necroptosis in apoptosis-resistant pancreatic carcinoma cells. *Cell Death Dis*. 2021;12(9):816.

184. Cheng R, Liu X, Wang Z, et al. ABT-737, a Bcl-2 family inhibitor, has a synergistic effect with apoptosis by inducing urothelial carcinoma cell necroptosis. *Mol Med Rep*. 2021;20(6):412.

185. Basit F, Cristofanon S, Fulda S. Obatoclax (GX15-070) triggers necroptosis by promoting the assembly of the necrosome on autophagosomal membranes. *Cell Death Differ*. 2013;20(9):1161-1173.

186. Thapa RJ, Nogusa S, Chen P, et al. Interferon-induced RIP1/RIP3-mediated necrosis requires PKR and is licensed by FADD and caspases. *Proc Natl Acad Sci U S A*. 2013;110(33):E3109-E3118.

187. Liu J, Guo M, Fan X. Ethanol induces necroptosis in gastric epithelial cells in vitro. *J Food Biochem*. 2020;45(4):e13692.

188. Bollino D, Balan I, Aurelian L, Valproic acid induces neuronal cell death through a novel calpain-dependent necroptosis pathway. *J Neurochem*. 2015;133(2):174-186.

189. Bao C, Sun Y, Dwarakanath B, et al. Carbon ion triggered immunogenic necroptosis of nasopharyngeal carcinoma cells involving necrototic inhibitor BCL-x. *J Cancer*. 2021;12(5):1520-1530.

190. Wu S, Zhou Y, Liu P, et al. MicroRNA-29b-3p promotes 5-fluorouracil resistance via suppressing TRAF5-mediated necroptosis in human colorectal cancer. *Eur J Histochem*. 2021;65(2). https://doi.org/10.4081/ejh.2021.3247.

191. Wu J, Chen X, Zhang J, et al. Tachyplesin induces apoptosis in non-small cell lung cancer cells and enhances the chemosensitivity of A549/DDP cells to cisplatin by activating Fas and necroptosis pathway. *Chem Biol Drug Des*. 2021;97(4):809-820.

192. Koo GB, Morgan MJ, Lee DG, et al. Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics. *Cell Res*. 2015;25(6):707-725.

193. Oliver Metzig M, Fuchs D, Tagscherer KE, et al. Inhibition of caspases primes colon cancer cells for 5-fluorouracil-induced TNF-α-dependent necroptosis driven by RIP1 kinase and NF-κB. *Oncogene*. 2016;35(26):3399-3409.

194. Choi MJ, Kang H, Lee YY, et al. Cisplatin-induced ototoxicity in rats is driven by RIP3-dependent necroptosis. Cells. 2019;8(5):409.

195. Yang H, Ma Y, Chen G, et al. Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy. *Oncoimmunology*. 2016;5(6):e1149673.

196. Lin CY, Chang TW, Hsieh WH, et al. Simultaneous induction of apoptosis and necroptosis by Tanshinone IIA in human hepatocellular carcinoma HepG2 cells. *Cell Death Discov*. 2016;2:16065.
197. Markowitsch SD, Juetter KM, Schupp P, et al. Shikonin reduces growth of docetaxel-resistant prostate cancer cells mainly through necroptosis. Cancers (Basel). 2021;13(4):882.

198. Kim HJ, Hwang KE, Park DS, et al. Shikonin-induced necroptosis is enhanced by the inhibition of autophagy in non-small cell lung cancer cells. J Transl Med. 2017;15(1):123.

199. Wang KJ, Meng XY, Chen JF, et al. Emodin induced necroptosis and inhibited glycolysis in the renal cancer cells by enhancing ROS. Oxid Med Cell Longev. 2021;2021:8840590.

200. Zhou J, Li G, Han G, et al. Emodin induced necroptosis in the glioma cell line U251 via the TNF-α/RIPI/RIP3 pathway. Invest New Drugs. 2020;38(1):50-59.

201. Li Y, Tian X, Liu X, et al. Bufalin inhibits human breast cancer tumorigenesis by inducing cell death through the ROS-mediated RIPI/RIP3/PARP-1 pathways. Carcinogenesis. 2018;39(5):700-707.

202. Lee YJ, Park KS, Lee SH. Curcumin targets both apoptosis and necroptosis in acidity-tolerant prostate carcinoma cells. Biomed Res Int. 2021;2021:8859181.

203. Deng Q, Yu X, Xiao L, et al. Neoaalconin induces energy depletion and multiple cell death in cancer cells by targeting PDK1-P13-K/Akt signaling pathway. Cell Death Dis. 2013;4(9):e804.

204. Jia Y, Wang F, Guo Q, et al. Curcumol induces RIPK1/RIPK3 complex-dependent necroptosis via JNK1/2-ROS signaling in hepatic stellate cells. Redox Biol. 2018;19:375-387.

205. Ali M, Mocarski ES. Proteasome inhibition blocks necroptosis by attenuating death complex aggregation. Cell Death Dis. 2018;9(3):346.

206. Martens S, Jeong M, Tonnus W, et al. Sorafenib tosylate inhibits necroptosis in acidity-tolerant prostate cancer cells. Eur J Pharmacol. 2017;8(6):e2904.

207. Fauster A, Rebsamen M, Huber KV, et al. A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis. Cell Death Dis. 2015;6(5):e1767.

208. Tu H, Zhou YJ, Tang LJ, et al. Combination of ponatinib with deferoxamine synergistically mitigates ischemic heart injury via simultaneous prevention of necroptosis and ferroptosis. Eur J Pharmacol. 2021;898:173999.

209. Chang L, Wang Z, Ma F, et al. ZYZ-803 mitigates endoplasmic reticulum stress-related necroptosis after acute myocardial infarction through downregulating the RIP3-CaMKII signaling pathway. Oxid Med Cell Longev. 2019;2019:6173685.

210. Lin PT, Xue XD, Zhao ZD, et al. Necrostatin-1, RIPI/RIP3 inhibitor, relieves transforming growth factor β-induced wound-healing process in formation of hypertrophic scars. J Cosmet Dermatol. 2021;20(8):2612-2618.

211. Harris PA, Berger SB, Jeong JU, et al. Discovery of a first-in-class receptor interacting protein 1 (RIPI) kinase specific clinical candidate (GSK2982772) for the treatment of inflammatory diseases. J Med Chem. 2017;60(4):1247-1261.

212. Harris PA, Marinis JM, Lich JD, et al. Identification of a RIPI kinase inhibitor clinical candidate (GSK3145095) for the treatment of pancreatic cancer. ACS Med Chem Lett. 2019;10(6):857-862.

213. Fakharnia F, Khodagholi F, Dargahi L, et al. Prevention of cyclophosphin D-mediated mPTP opening using cyclosporine-A alleviates the elevation of necroptosis, autophagy and apoptosis-related markers following global cerebral ischemia-reperfusion. J Mol Neurosci. 2017;61(1):52-60.

214. Ding J, Yang N, Yan Y, et al. Rapamycin inhibited photoreceptor necroptosis and protected the retina by activation of autophagy in experimental retinal detachment. Curr Eye Res. 2019;44(7):739-745.

215. Cao X, Jia G, Zhang T, et al. Non-invasive MRI tumor imaging and synergistic anticancer effect of HSP90 inhibitor and glycolysis inhibitor in RIPI-Tag2 transgenic pancreatic tumor model. Cancer Chemother Pharmacol. 2008;62(6):985-994.

216. Liang LS, Lu S, Yan WT, et al. The role of HSP90α in methamphetamine/hyperthermia-induced necroptosis in rat striatal neurons. Front Pharmacol. 2021;12:716394.

217. Wang Z, Guo LM, Wang Y, et al. Inhibition of HSP90α protects cultured neurons from oxygen-glucose deprivation induced necroptosis by decreasing RIP3 expression. J Cell Physiol. 2018;233(6):4864-4884.

218. von Mässenhausen A, Tonnus W, Himmerkus N, et al. Phenyltoin inhibits necroptosis. Cell Death Dis. 2018;9(3):359.

219. Wang Y, Ma H, Huang J, et al. Discovery of bardoxolon derivatives as novel orally active necroptosis inhibitors. Eur J Med Chem. 2021;212:113030.

220. Zhu J, Qu Z, Huang J, et al. Enantiomeric profiling of a chiral benzothiazole necroptosis inhibitor in RIP1-Tag2 transgenic pancreatic tumor model. Biomed Pharmacol Res. 2021;43:128084.

221. Wang J, Li Y, Huang WH, et al. The protective effect of aucubin from eucommia ulmoides against status epilepticus by inducing autophagy and inhibiting necroptosis. Am J Chin Med. 2017;45(3):557-573.

222. Meng XM, Li HD, Wu WF, et al. Wogonin protects against cisplatin-induced acute kidney injury by targeting RIPK1-mediated necroptosis. Lab Invest. 2018;98(1):79-94.

223. Qu C, Yuan ZW, Yu XT, et al. Patchouli alcohol ameliorates dextran sodium sulfate-induced experimental colitis and suppresses tryptophan catabolism. Pharmacol Res. 2017;121:70-82.

224. Al Shahrani M, Chandramoorthy HC, Alshahrani M, et al. Cissus auriculata leaf extract ameliorates diabetic nephropathy by attenuating autophagic necroptosis via RIP-1/RIP-3-p38 MAPK signaling. J Food Biochem. 2021;45(7):e13810.

How to cite this article: Liu X, Xie X, Ren Y, et al. The role of necroptosis in disease and treatment. MedComm. 2021;2:730–755. https://doi.org/10.1002/mco2.108